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palavras-chave 
 
Proteína 1B associada com a lâmina (LAP1B); membrana interna nuclear 
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resumo 
 
 
A proteína 1B associada com a lâmina é uma proteína intrínseca da membrana 
interna nuclear que está abundantemente expressa nos tecidos neuronais, 
nomeadamente no estriado, tronco cerebral e cerebelo. A LAP1 está 
associada com a lâmina nuclear e pensa-se que estabiliza a arquitetura do 
invólucro nuclear (NE). A função da LAP1B ainda não é compreendida, mas 
pensa-se que serve de local de ligação entre a lâmina e a membrana interna 
nuclear. Além disso, a LAP1 pode estar também envolvida na organização dos 
microtúbulos do fuso mitótico durante a mitose. Uma vez que a função da 
LAP1 não é conhecida, induziu-se o knockdown em células de neuroblastoma 
humanas através da estratégia de RNA de interferência pela variante short 
hairpin, para mimetizar o comportamento da célula na ausência da LAP1. 
Através de immunoblotting e de microscopia de fluorescência, confirmou-se a 
diminuição dos níveis da LAP1B, assim como da LAP1C, uma isoforma ainda 
não sequenciada até ao momento. Novamente, por immunoblotting, os níveis 
intracelulares da lâminaB1, α-tubulina acetilada e da Polimerase poli ADP-
Ribose (PARP) foram avaliados por uma análise global da integridade celular. 
Por microscopia confocal, a morfologia dos núcleos celulares e a distribuição 
da α-tubulina acetilada foram observados para analisar a integridade do 
invólucro nuclear. Os nossos dados sugerem que a LAP1B parece ser 
essencial para a distribuição da α-tubulina acetilada e, consequentemente, 
para a estabilidade dos microtúbulos durante a mitose. Existem evidências que 
a outra isoforma parece desempenhar um papel mais importante na morfologia 
e integridade do invólucro nuclear. Ambas as isoformas parecem desempenhar 
um papel essencial na regulação da mitose. Contudo, são necessários estudos 
adicionais para confirmar estes resultados e desvendar a função específica 
das isoformas da LAP1 durante a mitose. 
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abstract 
 
Lamina-Associated Polypeptide 1 (LAP1) is a type two integral inner nuclear 
membrane (INM) protein that is abundantly expressed in neural tissues, namely 
striatum, mid-brain and cerebellum. LAP1 protein is associated with nuclear 
lamina, which is thought to stabilize the nuclear envelope (NE) architecture. 
The function of LAP1 protein is not already understood but it is thought to 
function as a lamina attachment site into the inner nuclear membrane (INM). 
Additionally, LAP1 may also be involved in assembly of mitotic microtubule 
spindle during mitosis. Since the function of LAP1 remains unknown, we 
induced the knockdown of LAP1, in human neuroblastoma cells, through the 
short hairpin RNA interference strategy, in order to mimic the cellular behavior 
in the absence of LAP1. Through immunoblotting and fluorescence microscopy, 
we confirmed the decrease of intracellular levels of LAP1B as well as in 
another isoform not sequenced so far. Once more, through immunoblotting, the 
levels of laminB1, acetylated α-tubulin and cleaved poly ADP-Ribose 
Polymerase (PARP) were evaluated for an overall analysis of cellular integrity. 
By confocal microscopy, cell nuclei morphology and acetylated α-tubulin 
distribution were observed to analyze the nuclear envelope integrity. Our data 
suggest LAP1B seems to be essential for acetylated α-tubulin distribution and, 
therefore, for microtubule stability during mitosis. There is evidence that the 
other isoform seems to play a more pronounced role in nuclear envelope 
integrity and morphology. Together, both isoforms seem to play an essential 
role in mitosis regulation. However, further studies are required to confirm 
these results and unravel the specific function of LAP1 isoforms during mitosis. 
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1. EUKARYOTIC CELL NUCLEUS 
The eukaryotic cells are essentially constituted by the plasma membrane, the 
cytoplasm (containing the cytosol, cytoskeleton and cell organelles) and the nucleus. The 
latter is a highly specialized and spherical-shaped organelle that is enclosed within the 
nuclear envelope (NE), which delimits the nuclear content from the cytoplasm components, 
separating the activity of both cellular compartments (Figure 1A). The nucleus is the most 
prominent cell organelle which contains the genetic information packaged into chromatin, 
which is composed of DNA and chromosomal proteins (histones). Additionally, the nucleolus 
is also a nuclear component, where the rRNA is synthesized, as well as nucleoplasmic fibrils 
that are involved in processing and transport of mRNA to cytoplasm. Therefore, the nucleus is 
considered a quite essential organelle for genome integrity and stability, DNA replication and 
gene expression (1–3).  
The nuclear envelope connects the nucleus and the cytoplasm through the linker of 
the nucleoskeleton and cytoskeleton complex (LINC), which is formed by integral SUN 
proteins of the inner nuclear membrane (INM) and nesprin proteins of the outer nuclear 
membrane (ONM). The NE is essentially composed of nuclear pore complexes (NPCs), the 
nuclear lamina and the double-membrane system that comprises the INM and the ONM 
(Figure 1B) (3–5). The NPCs are protein structures with different polypeptides subunits, which 
join both nuclear membranes, allowing the exchange of some substances between cytoplasm 
and nucleoplasm. Between the dual membrane there is also a perinuclear lumen separating 
the INM and ONM (3,4,6). 
The nuclear lamina is a fibrous network of protein fibrils that can be interpreted as a 
cytoskeletal structure, since it is composed by intermediate filaments and membrane 
associated proteins (5,7). Accordingly, lamina is quite important for cell structure and 
mechanic stability. The nuclear lamina is composed of several proteins known as lamins, 
which were also found in nucleoplasm beyond their concentration in nuclear periphery (8). 
Such findings suggested that lamins may be required for cell cycle regulation, chromatin 
organization, DNA replication, differentiation as well as apoptosis (2,9). Furthermore, lamins 
also bind chromatin and function as anchoring site, for instance, for interphase chromosomes 
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and membrane associated proteins. It has been suggested that lamina controls the assembly 
and reformation of NE, its size and shape (5,7,10). 
 
Figure 1 - Schematic representation of the nuclear envelope and nuclear membranes. A) The NE is a 
double-membrane system, continuous with the ER, which encloses the nuclear compounds, essentially the 
nucleolus, nuclear lamina and chromatin. Among nuclear membranes there is a lumen termed perinuclear 
space. B) The NE is comprised of a dual membrane divided into the ONM and INM. This double membrane 
system separates nuclear contents from the cytoplasm. Both membranes are joined by NPCs, which also 
appear to regulate the transport between nucleus and cytoplasm. The ONM is biochemically similar to 
peripheral ER and the INM contains a set of integral membrane proteins, many of which bind to lamins 
and/or to chromatin. In higher eukaryotes, the NE is lined by a protein network, the nuclear lamina, which is 
an attachment site for NPCs and chromatin. ER, inner nuclear membrane; INM, inner nuclear membrane; 
NE, nuclear envelope; NPC, nuclear pore complex; ONM, outer nuclear membrane. Adapted from (11,12).  
 
In mammalian eukaryotic cells, the nuclear lamina mainly contains one to four nuclear 
lamins that are type V intermediate filament proteins. They are classified as lamins A, B1, B2 
and C and are similar to intermediate filaments in their structure and biochemical properties. 
Additionally, lamins can be categorized according to their primary sequence and expression 
pattern as A-type and B-type lamins. The A-type lamins comprises the lamin A and lamin C, 
which are alternatively spliced products of the same gene, the LMNA gene, being only 
expressed in differentiated cells and tissues (13). The B-type lamins are expressed in every 
embryonic and somatic tissues studied. In vertebrates, lamins B1 and B2 are specialized for 
meiosis and early embryogenesis and have a similar sequence but they arise from different 
genes, the LMNB1 and LMNB2 genes, respectively. The lamins share a common globular N- 
and C-terminal domains and a nuclear-localization signal (NLS) close to four α-helical 
segments (coil 1a, coil 1b, coil 2a and coil 2b) that are separated by a non-α-helical linker 
sequence. The lamin structure is represented in Figure 2 (2,3,5).  
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Figure 2 - Generic lamin structure with several characteristic domains. Lamins comprise a helical rod 
domain highly conserved among all intermediate filament proteins, the head and tail domains. Within the 
tail domain, there is a NLS and an Ig fold. Most lamins contain at their C-terminal a CAAX motif that allows 
chemical reactions, leading to protein modification. Ig, immunoglobulin; NLS, nuclear-localization signal. 
Taken from (14).  
The outer nuclear membrane is continuous with the rough endoplasmic reticulum 
(ER), containing few proteins, like nesprins, and is covered by ribosomes. In turn, the INM is 
continuous with the nuclear lamina and includes a particular group of integral membrane 
proteins (Figure 3), which interact with nuclear lamins, remaining closely associated with the 
nuclear lamina (2,3,15). As shown below, the INM proteins include, for example, the firstly 
identified Lamin B Receptor (LBR), SUN proteins, MAN1/LEMD3 (LEM domain-containing 
protein 3), Emerin and the Lamina-Associated Polypeptides (LAPs). The latter will be 
extensively discussed during this work.  
 
Figure 3 - Inner nuclear membrane proteins and their associations with lamina and nuclear contents. The 
INM is associated with the nuclear lamina and chromatin. The integral INM proteins like LBR, SUN, emerin, 
LAP1 and transmembrane isoforms of LAP2 bind to lamina components and chromatin. SUN proteins of the 
INM bind to nesprins in the ONM, composing the LINC complex. SUN proteins bind to lamins and some 
nesprin isoforms bind to cytoskeletal proteins, like actin. INM, inner nuclear membrane; LAP, lamin-
associated polypeptides; LBR, lamin B receptor; LINC, linker of nucleoskeleton and cytoskeleton complex; 
NPC, nuclear pore complex; ONM, outer nuclear membrane. Adapted from (16).  
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2. INNER NUCLEAR MEMBRANE PROTEINS 
Integral proteins of the inner nuclear membrane are synthesized on the rough ER and 
reach the INM through lateral diffusion where they are retained by nuclear ligands (17). The 
INM is composed of approximately 70 transmembrane proteins, many of which interact with 
the nuclear lamina and/or chromatin proteins, being related with chromatin organization and 
postmitotic reassembly of the nucleus (18). As mentioned before, among the INM proteins 
are lamin B receptor (LBR), MAN1, Emerin, SUNs and LAPs. Loss-of-function studies in biologic 
models suggested that proper expression of several integral INM proteins is essential for 
normal development (11,14). For example, the loss of expression of the LBR leads to the 
aggregation of heterochromatin in the nuclei of neutrophils, showing to be essential for their 
morphological maturation (19). Additionally, it is known that loss of emerin in humans causes 
significant cardiac and skeletal muscle disease and the deletion of genes encoding SUN 
proteins mainly results in cell migration and nuclear positioning defects (14,20).  
2.1. Lamina-Associated Polypeptides 
Lamina-associated polypeptides (LAPs) are integral membrane proteins, since they are 
permanently attached to the inner nuclear membrane. Thus, LAPs are biochemical markers 
for INM integrity and are very useful models for nuclear membrane biogenesis studies (5).  
Most of NE membrane proteins are localized in the INM, including LAPs that were 
primarily identified in NE fractions extracted from rat livers. These results were achieved by 
immunogold labeling of the RL13 and RL29 antibodies that recognizes LAPs. Therefore,  the 
latter were specifically localized  in INM (4,5). Three rat LAP1 isoforms were identified: LAP1A, 
LAP1B, LAP1C through RL13 antibody and another distinct protein, LAP2, was detected by the 
RL29 antibody (4,5,15). 
Fluorescence microscopy analysis of both LAP1 and 2 revealed that they are localized 
in the nuclear periphery. Therefore, is reasonable to deduce that both variants may be 
involved in attaching lamins to the NE, since the co-localization of LAPs and lamins is quite 
similar (Figure 4). The association between LAPs and nuclear lamina was also supported by 
the results of chemical extraction of NE, which showed the presence of almost the entire 
LAP1A, B and LAP2 in the pellet along with insoluble lamins. Regarding LAP1, the localization 
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of RL13 epitope on nucleoplasm, where lamina is found, also contributed to this conclusion 
(4).  
 
Figure 4 - Immunolocalization of B-type lamins and LAPs (LAP1 and LAP2). Immunofluorescence 
microscopy images of the lamin, LAP1 and LAP2 during the prophase. LAP1, LAP2 and lamin B are well 
localized in perinuclear region during prophase. LAP, Lamin-Associated Polypeptides. Adapted from (21). 
LAP2 proteins are type two integral membrane proteins that are also divided into 
isoforms, , , , , and , which are products of alternative splicing of a single individual 
gene, TMPO. Some findings show that LAP2 associates only with lamin B1 and directly with 
chromosomes, when the protein is phosphorylated. It is likely that LAP2 may play a role in 
initial reassembly of NE and also in the association between membrane and chromosomes 
(2,4). 
2.1.1. Lamina-Associated Polypeptides 1 (LAP1) 
2.1.1.1. LAP1 topology and tissue distribution 
Integral membrane proteins can be synthesized differently and they assume different 
types, depending on its organizational structure. LAP1s are type two integral membrane 
proteins, since their amino-terminal domains face the nucleoplasm, being potential binding 
partners of nuclear proteins (17,22). LAP1 includes a long hydrophilic N-terminal 
nucleoplasmic portion, a single hydrophobic transmembrane domain and a shorter lumenal 
C-terminal domain (Figure 5). The conserved C-terminal and transmembrane domains are 
encoded by a single exon in both in rat, mouse and human, suggesting that LAP1 isoforms 
differ only in their nucleoplasmic domain (2,23).  
Kyte/Doolittle hydrophobicity analysis revealed that rat LAP1C has a single 
transmembrane domain located between residues 311-333. Based on that, residues 1-311 
could be located on the nucleoplasm and residues 334-506 in the perinuclear space or vice 
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versa. The topology of rat LAP1s was established using the anti-LAP1 RL13 antibody (6). The 
RL13 epitope was  shown to localize in the nucleoplasm (5). Several deletion constructs of rat 
LAP1C were prepared to determine whether they are immunoadsorbed by anti-LAP1 RL13. 
Full-length LAP1C and the deletion construct comprising amino acids 1-325 was 
immunoadsorbed by RL13 antibody. A construct where the residues 129-303 were deleted 
was unreactive with RL13 antibody. Therefore, a nucleoplasmic localization of the amino-
terminal sequence of LAP1C was established and, consequently, the C-terminal is confined to 
lumenal domain, located within membranes as represented in Figure 5 (6). 
 
Figure 5 - Schematic representation of LAP1 protein structure. LAP1 protein is an inner nuclear membrane 
protein, which is composed by a N-terminal domain localized in the nucleoplasm, a TM domain and a 
shorter C-terminal domain localized in the lumenal space. The later domains are encoded by only a single 
exon (common to all isoforms) while the longer N-terminal of LAP1 sequence is the site where the 
alternative splicing occurs, yielding the three isoforms of the protein: LAP1A, LAP1B and LAP1C. ER, 
endoplasmic reticulum; INM, inner nuclear membrane; LAP1, lamin-associated polypeptide 1; ONM, outer 
nuclear membrane; TM, transmembrane. Adapted from (23). 
LAP1s are closely related INM proteins present in most cell types, being expressed in 
both neural and non-neural tissues (Figure 6). LAP1 protein is essentially present in striatum, 
mid-brain and cerebellum, concerning to neural tissues. Additionally, LAP1 is abundantly 
expressed in non-neural tissues, namely the kidney, liver and heart (23,24). 
 
Figure 6 - Tissue distribution of mouse LAP1. RT-PCR of mouse LAP1 from whole extracted tissue RNA.  LAP, 
Lamin-Associated Polypeptides; RT-PCR, Reverse Transcription Polymerase Chain Reaction. Taken from (23). 
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2.1.1.2. LAP1 isoforms 
LAP1 protein is expressed in three isoforms in rat, LAP1A, LAP1B and LAP1C, resulting 
from alternative splicing of the same gene: TOR1AIP1 (1,6,25). The isoforms are closely 
related based on their cross-reaction with RL13 antibody (6). However, they differ in the N-
terminal region and their expression during development is supposed to be distinct. These 
alterations of expression may contribute for nuclear structure regulation (5,6,26). Such 
information was obtained from several rat studies, since the information about rat LAP1 
sequences is known and available: rat LAP1C isoform was the only full-length cDNA 
sequenced (6). A class of rat LAP1 cDNAs was isolated, which contains two protein-coding 
nucleotide insertions in LAP1C sequence. These probably encode part of rat LAP1A/B, since 
the isolation of independent LAP1C-like cDNAs are likely to contain partial length clones 
derived from LAP1A/B. Thus, rat LAP1A and 1B sequences were partially characterized since 
they are believed to consist of rat LAP1C with 2 additional insertions (1,25). 
Rat LAP1A is the 75 kDa LAP1 isoform, which seems to have the strongest association 
with lamins A, B1 and C. As LAP1A, rat LAP1B (68 kDa) strongly interacts with these same 
lamins (2,4,6). Both isoforms interact indirectly with mitotic chromosomes (4–6). The rat 
LAP1C (55 kDa) is the only rat LAP1 isoform with a complete determined 506 aminoacid 
sequence (6) and the most abundant in cultured cells (4,6,21). LAP1C was not shown to 
interact with any lamin in vitro, but there are evidence of association with lamin A and C in 
vivo (4). The nuclear localization of LAP1C is likely to change, depending on lamin A presence 
and seems to be the only integral protein capable of moving between nucleus and cytoplasm. 
It was reported the LAP1C translocation between INM and ONM in undifferenciated murine 
embryonal carcinoma P19 cells. However, when the cells were transfected with lamin A, 
LAP1C accumulated at the INM, what suggests lamin A as a potential LAP1C binding protein. 
(10). Other research reports that LAP1C might be part of a multimeric complex including the 
LAP1A isoform and B-type lamins, for example (2,10).  
Regarding LAP1 isoforms in humans, less information is available. In fact, no evidence 
of a predicted human LAP1A was seen until now and human LAP1C (huLAP1C) is only partially 
known. Two additional insertions in one huLAP1C clone were reported when it was compared 
with human LAP1B (huLAP1B) (25), as previously described for rat LAP1C and LAP1B (6). 
Unpublished data from our laboratory indicated that at least two isoforms are present in 
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humans (Figure 7). The 68 kDa isoform corresponds to the well characterized huLAP1B and 
the other, for comparison with rat isoforms, it is believed to be huLAP1C. These results are 
now being confirmed by mass spectrometry (Santos, M., unpublished data). However, at this 
moment, this is only a putative huLAP1C but, for simplicity, for now long we will always call it 
huLAP1C, during this work. 
 
 
Figure 7 - Human LAP1B (68 kDa) and human LAP1C (55 kDa) isoforms in SH-SY5Y cells. huLAP1B, human 
LAP1B; huLAP1C, human LAP1C. 
2.1.1.3. Human LAP1B isoform 
The gene TOR1AIP1 encodes 10 exons which are localized on chromosome 1 (1q24.2). 
The huLAP1B protein includes 584 aminoacids and has no significant homology with known 
two type INM proteins (23,25,27).  
As previously mentioned in LAP1 structure, it includes a short lumenal C-terminal, a 
single transmembrane domain and a longer nucleoplasmic N-terminal. The C-terminal 
lumenal domain is highly conserved, in spite of its function is being unclear. However, there is 
a putative regulatory role for maintenance of nuclear structure and organization. The 
huLAP1B is retained within the nucleus through interactions of the nuclear components with 
the nucleoplasmic portion of the protein. The N-terminal nucleoplasmic domain is responsible 
for interaction with lamins as well as chromosomes and, together with the transmembrane 
(TM) span, it allows the proper localization of huLAP1B within the nucleus (25,28). 
Additionally, the N-terminal includes several phosphorylation sites. Nevertheless, the 
function of LAP1 phosphorylation is still poorly understood (27). A bioinformatic approach of 
huLAP1B also revealed the presence of a nuclear receptor box motif (NRBOX) in the lumenal 
domains, which allows binding to a nuclear receptor (27). 
In order to clarify the function of huLAP1B and its targeting mechanism to INM, it 
would be significant to recognize the binding proteins and explore them (25). It was shown 
that huLAP1B nucleoplasmic domain interacts directly with lamins A, C and B1 and possibly 
indirectly with chromsomomes (4,5). Moreover, the lumenal domain of LAP1 was found to 
68 kDa
55 kDa
huLAP1B
huLAP1C ?
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associate with torsinA (torA) (23), the protein involved in DYT1 dystonia (further described). 
In addition, LAP1 co-immunoprecipitated with all four members of the human torsin family: 
torsinA, torsinB, torsin2 and torsin3 (29). Recently, huLAP1B was found to interact with 
protein phosphatase 1 (PP1) in yeast two hybrid screens(27,30,31). Specifically, PP1 interacts 
with huLAP1B though a known PP1 binding motif located in the nucleoplasmic domain. Thus, 
huLAP1B may be dephosphorylated by PP1 (27). Indeed, LAP1 was found to be 
phosphorylated in several residues, but the kinases involved are not well described. However, 
rat LAP1B was found to be phosphorylated by cyclin-dependent kinase 1 on Ser142 
(homologous to huLAP1B Ser143) (32). 
2.1.1.4. LAP1 putative functions 
The function of LAP1 remains unclear, although it has been hypothesized that LAP1 
isoforms may have a role as lamina attachment sites and assembly in the INM (4–6). 
Additional putative functions have been related with the arrangement and structure of lamin 
filaments and reassembly of the NE at the end of mitosis (7). Since torsinA is an interacting 
protein of huLAP1, it is being hypothesized that LAP1 is a substrate or a cofactor of torA, 
though it is not totally clear yet. LAP1 may be responsible for catalytically activate torsinA 
AAA+ function (ATPAse associated to several cellular activities), stimulating ATP hydrolysis. 
Thus, LAP1 may work as a positive regulator of torA ATPAse activity (23,33). Additionally, a 
recent report suggests that LAP1 is associated with the mitotic microtubule spindle assembly 
(29). Such putative function arose from a LAP1 knockdown approach, in which the spindle 
formation was impaired in prometaphase. Thus, the centrosomes only formed weak mitotic 
asters and failed to align chromosomes, leading to cell death (34). 
2.1.1.5. LAP1 interaction with lamins during mitosis 
During mitosis, the nuclear membranes lose their identity as a subcompartment of the 
ER, supporting the notion that the sorting of specific membrane proteins to the NE is driven 
by binding interactions at chromosome surfaces, at the end of the mitotic process (7). Thus, 
LAP1 is dispersed throughout the ER membranes, however, depending on the mitotic phase 
(Figure 8), LAP1 localization may diverge slightly (7).  
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Figure 8 - Distribution of inner nuclear membrane proteins during mitosis. A) The interphase NE is 
morphologically continuous with the peripheral ER but is a specialized ER subcompartment that contains 
integral membrane proteins specific to the INM. For instance, the LAP1 forms multimeric assemblies which 
are associated with B-type lamins during interphase. B) The NE breaks down in prophase and it becomes 
difficult to distinguish it from other components of the peripheral ER. Here, inner nuclear proteins as LAP1 
seemed to remain localized all over the ER, as well as in metaphase. C) It was proposed that proteins are 
resorted to the NE during late anaphase and subsequently associate with binding sites at the chromosomes. 
Reformation of the NE may involve cooperative assembly of lamins and integral proteins of the INM. ER, 
endoplasmic reticulum; INM, inner nuclear membrane; LAP1, lamin-associated polypeptides 1; NE, nuclear 
envelope; ONM, outer nuclear membrane. Adapted from (7). 
During interphase, LAP1 forms multimeric assemblies which are associated with B-
type lamins. LAP1 was visualized in a nuclear edge pattern in the ER, whose membranes were 
seen as a widespread vesicular network extending from the nuclear envelope to the cell 
periphery (7,21). Afterwards, in prophase, the NE breaks down and it becomes difficult to 
distinguish it from other components of the peripheral ER, where LAP1 is also present 
homogeneously. Then, the NE is disassembled in prometaphase, during which LAP1 seemed 
to remain localized all over the entire ER, as well as in metaphase, persisting until the mid-
anaphase (7). Subsequently, in late anaphase, nuclear membranes reassemble through the 
association of membrane vesicles with chromosome surfaces and through the membrane 
fusion. Thus, there are evidence of LAP1 starting to be segregated from endoplasmic 
membranes at chromosomes periphery (4,7). In addition, in some late anaphase cells, LAP1 
remaining in the peripheral ER were not uniformly localized, but appeared to be concentrated 
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in particular elements of ER. Finally, LAP1 was exclusively perinuclear during the telophase, in 
which it was more concentrated because of the increasing of the nuclear envelope surface 
area and the reduced synthesis of other proteins (7).  
2.1.1.6. LAP1 interaction with torsinA 
The torsinA (torA) protein is one of the LAP1 interacting proteins, which deserves 
particular emphasis. LAP1 is also termed torsinA interacting protein 1 (tor1AIP1) due to LAP1-
torsinA interaction, which occurs via the conserved lumenal domain of LAP1 that is common 
to all LAP1 isoforms (23,35). TorsinA is primarily located in the ER (36) but it was also found in 
the NE. The mutant form of torA, which causes DYT1 dystonia, is relocated to the NE (37). 
LAP1 lumenal domain (LD) was shown to be implicated in controlling the subcellular 
localization of torA, since LAP1 seems to recruit torsinA to the NE. This conjecture derives 
from the observation that the ectopic expression of LAP1 constructs that include the LDs 
change the  subcellular localization of TorA, but constructs that lack them do not. Afterwards, 
it was concluded that LAP1 associates with torA (Figure 9), preferentially in its ATP-bound 
form, through LD interaction (23,33). 
 
Figure 9 - Schematic representation of INM proteins and nucleoplasmic proteins, specifically LAP1 and 
torsinA interaction in perinuclear space. TorsinA interacts with lumenal domain of LAP1. INM, inner nuclear 
membrane; LAP1, lamina-associated protein 1. Adapted from (13). 
 
The torsinA protein is encoded by the TOR1A/DYT1 gene that includes 5 exons and is 
located on chromosome 9q. The torA is a 332-aminoacid protein that belongs to torsin 
proteins family, which are members of the AAA+ ATPases superfamily. TorA is predominantly 
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localized in the continuous lumen of the ER and NE. This protein is broadly expressed in 
human tissuess but it seems to play the most critical role in the central nervous system, since 
it is abundantly expressed during development. In adulthood, the expression of torsinA is 
higher in dopaminergic neurons in substantia nigra pars compacta, striatum, cortex, 
thalamus, hippocampus, cerebellum, brainstem and spinal cord. TorA has been implicated in 
several cellular central nervous system pathways including NE integrity, cytoskeleton 
organization, degradation of misfolded proteins, ER stress sensitivity, dynamics of secretory 
and synaptic vesicles and modulation of dopamine neurotransmission (38).  
TorsinA assembles into the hexameric structure of an active AAA+ protein and 
contains an N-terminal ER signal sequence (SS), a hydrophobic region (Hypb) and the 
characteristic AAA+ domain. The latter domain contains the Walker A and Walker B motifs 
(responsible for ATP hydrolysis), the ATP sensing motifs (sensor I and II) and six conserved 
cysteine residues. The torsinA structure is represented in Figure 10 (24,38).  
 
Figure 10 - Schematic representation of torsinA protein. The torsinA includes a signaling sequence, a 
hydrophobic domain and the AAA
+ 
domain. The AAA
+
 domain consists of Walker A/B motifs (green), sensor 
I/II (orange) motifs, and six conserved cysteines. AAA
+
, ATPases associated to several cellular activities; 
Hypb, hydrophobic; SS, signaling sequence. Adapted from (38). 
 
LAP1 has been associated with torsinA in the NE, since LAP1 null mice, homozygous 
lacking tor1A and mutated tor1A share the same abnormal membrane perinuclear inclusions 
that could not be morphologically distinguished from each other. In heterozygous TOR1AIP1 
knockout mice there were no alterations from wild-types. On the other hand, the 
homozygous lacking LAP1 exhibited such membrane bound protuberances derived from the 
INM. It is often termed bleb formation, which abnormally happens in all brain regions and 
also in many different non-neural tissues, including the liver, kidney, striated muscle and skin. 
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Moreover, it was observed perinatal lethality in homozygous TOR1AIP1 deleted mice which 
was indeed a very curious and important finding (29). 
The ultrastructural changes were visualized in all investigated brain areas, namely 
striatum, thalamus, cortex and spinal cord, and it seems to impair the interaction torsinA-
LAP1 in addition to other binding protein associations. Thus, these observations may mean 
that torsinA and LAP1 are involved in a widespread biological process to which neurons are 
more susceptible and, in this way, LAP1 may play a role in a torsinA pathway, which is central 
in DYT1 dystonia, discussed briefly later (29). 
3. IMPACT OF THE INNER NUCLEAR MEMBRANE PROTEINS ON HUMAN DISORDERS 
In spite of several diseases be attributable to defects in the NE, its molecular structure 
remains poorly understood. Alterations in the nuclear membrane may contribute to disease 
through increased fragility of the nucleus under mechanical stress, structural alterations in 
chromatin or misregulation of transcription factors, all of which culminate in changes in gene 
expression (39). 
The INM and the lamina seem to have crucial roles in fundamental processes for 
human health, such as the function of striated muscle, osteogenesis, lipid and glucose 
metabolism and aging. Thus, an increasing number of  diseases have been associated to 
genes encoding for lamins, integral proteins of the INM and associated proteins, some 
referred as laminopathies (3). Laminopathies comprise a heterozygous inherited group of 
disorders that include muscular dystrophies, lipodystrophies and premature aging syndromes, 
caused by nuclear lamina alterations (13,39). Mutations in the gene encoding for A-type 
lamins origin several inherited disorders whose injured tissue differs according to the type of 
mutation. These mutations can affect striated muscle, adipose tissue or multiple systems. For 
instance, the Emery-Dreifuss muscular dystrophy is one of the most prevalent muscular 
dystrophies in adulthood as well as the Hutchinson-Gilford progeria syndrome with a 
premature aging phenotype and the Dunnigan-type familial dystrophy affecting adipose 
tissue (2,3). 
Interestingly, a movement disorder called DYT1 dystonia may also involve huLAP1 
protein, since it interacts with torsinA (mutant protein in DYT1 dystonia) and shared similar 
phenotypes when they were deleted (29). The term “movement disorders” has been evolving 
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over the years and it represents a set of neurologic dysfunctions based on clinical patterns, in 
which there is either an excess of motility or a loss of voluntary and autonomous movements. 
The first group characterized by excessive motion includes the hyperkinesias (uncoordinated 
and exaggerated movements), dyskinesias (abnormal movements) and atypical involuntary 
actions. The hypokinesia (decreased amplitude of movement), bradykinesia (slowness of 
motility) and akinesia (movement loss) are integrated in the movement loss group (40). Here, 
we will focus on DYT1 dystonia since it is the third most prevalent movement disorder in 
humans, following the essential tremor and Parkinson’s disease, where it is believed that 
huLAP1 could be involved (38,41). 
The term “dystonia” was first used by Oppenheim in 1911 and its definition and 
classification have changed over time (40). This movement disorder may also be referred as a 
basal ganglia disorder, since patients with secondary dystonia have lesions in these limbic 
structures (38). Torsion dystonia has been recognized as a hyperkinetic movement disorder 
that involves involuntary and sustained muscle spasms that forces twisting and repetitive 
movements or irregular postures without presenting significant structural brain abnormalities 
(40,42). Occasionally, dystonic movements are exacerbated by a specific task, such as writing, 
which is called Writer’s Cramp Dystonia (43).  
It has been demonstrated that dystonia affects 15 to 30 per 100 000 people. Primary 
Torsion Dystonia (PTD) accounts for around 75% of dystonic patients and it mainly affects 
people over fifty years of age, which suggests that it is quite common among aging 
population. A higher prevalence in Ashkenazi Jews was also reported, which is the result of a 
mutation that arose about 350 years ago. Dystonia can be classified triply based on age of 
onset, etiology and its distribution throughout the body (43,44).  
This neurologic disorder can occur at any age and it can be divided into early (<26 
years) and late onset (>26 years) (43). The age of onset is important because it provides 
information about the prognosis of dystonia. Normally, the most severe is the DYT1 dystonia 
which, in turn, can be subdivided into DYT1 early onset generalized dystonia and non-DYT1 
early onset dystonia (40,45). In what concerns to the symptoms distribution, torsion dystonia 
can manifest itself as localized in a particular region, segmental (continuous in two regions of 
body) or multifocal. On the other hand, dystonia can be generalized or only affect one side of 
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the body (hemidystonia) (43). The etiology approach involves two main dystonia types: the 
primary and secondary dystonia. The most frequent variant, primary torsion dystonia, occurs 
when the phenotype arises spontaneously without any existing cause, related disease or 
neurodegeneration. Focal cervical dystonia is the most recurrent type of focal PTD, which 
results in aberrant shoulder, neck and head positions. The secondary dystonia has an 
acquired cause as a result of an environmental factor or brain lesions, namely in basal ganglia, 
and it describes additional symptomatic features. The usual affected neurologic structures are 
the caudate, globus pallidus, putamen and thalamus. Furthermore, there are also evidence of 
cerebellar and brainstem impairment (38,40). Additionally, it is known the “primary-plus 
dystonia” and the heredodegenerative dystonia. The first is associated with other movement 
disorder, such as parkinsonism, in the absence of neuronal degeneration and the latter 
emerges in a context of a neurodegenerative disorder, such as Huntington’s disease (38,43). 
The TOR1A gene, encoding the torsinA protein, is involved in the most common form 
of dystonia, the DYT1 dystonia. Thus, the DYT1 has been the most studied variant because it 
is one of the few forms of the disease with a consistent gene mutation found in a great 
number of patients (28,38,45). The most frequent cause of early onset PTD (around 70%) is a 
mutation in the coding region of the TOR1A gene resulting in a deletion of three base pairs 
(ΔGAG) in exon 5, that originates a loss of one glutamate residue (ΔE302/303) near the C-
terminal of torsinA (Figure 11). This mutation is normally referred as mutant torsinAΔE 
(26,38,42). 
 
Figure 11 - Diagram of TOR1A gene and torsinA protein. The TOR1A gene is composed of five exons and 
the torsinA protein has 332 aminoacids. The mutated TOR1A gene comprises a GAG deletion in exon 5, 
which results in loss of one glutamate residue (ΔE302/303) near the C-terminus. This mutation is the most 
common cause of early onset dystonia. 
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In spite of the mutated torsinAΔE be responsible for most cases of early onset torsion 
dystonia, as referred previously, it is believed huLAP1 is also involved in the torsinA pathway, 
in which a disruption of interaction among both may contribute to DYT1 dystonia 
pathogenesis (26,28,29,35). 
4. RNA INTERFERENCE STRATEGY 
The RNA interference (RNAi) approach is a natural specific and selective process, 
through which expression of a targeted gene is knocked down by a double-stranded RNA 
homologous to its own gene to mimic what happens at a cellular level, if it is absent or weakly 
expressed. Thus, RNAi is part of the loss-of-function methods such as gene silencing, which 
represent powerful strategies for unraveling the putative gene function in mammalian cells 
(46–48). Furthermore, this strategy has been recognized as an effective and resourceful tool 
in biomedical science which can also be performed in large-scale functional genomics 
experiments and it has been progressively expanded to clinical field and as a way of gene 
therapy (48). Despite post-translational gene silencing has been firstly observed in petunia 
plants, the underlying mechanism was not yet well defined and understood (46,47,49,50). In 
this case, a gene copy that encodes an enzyme responsible for the anthocyanin floral 
pigment, chalcone synthase, was inserted into the plants. Surprisingly, it was shown a 
suppression of the endogenous gene function caused by this additional copy (49,51). Later on 
1998, the RNA interference process was described, by Andrew Fire and Craig (52) who tested 
it using a nematode worm biological model Caenorhabditis elegans, whose genome has been 
discovered through this same process. In these experiments, it was induced sequence-specific 
gene silencing through the introduction of exogenous dsRNA (46,47,50,51). Afterwards, the 
RNAi technique was also estabilished in a large range of organisms, such as Drosophila, 
trypanosomes, planaria, hydra, zebrafish and mammalians (47,50). 
The current model of the RNAi mechanism involves two steps, the initiator and the 
effector (50,53,54). The first step involves the digestion of the exogenous double-stranded 
RNA (dsRNA) into small interfering RNAs (siRNAs) mediated by the Dicer enzyme (Figure 12A), 
which is member of the RNAse III family of dsRNA-specific ribonucleases (55). The cleavage of 
the dsRNA is dependent of ATP, generating 19 to 21 basepairs siRNA duplexes with a 3' 
overhang of two nucleotides. The effector step is achieved when the duplexes bind to a 
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multicomponent nuclease complex and form the RNA-induced Silencing Complex (RISC) 
(Figure 12A). The latter is then activated by the ATP-dependent unwinding of the siRNA and, 
subsequently, the complex binds to the substrates through their homology to siRNA by base 
pairing. The mRNA is targeted for destruction through its cleavage at approximately 12 
nucleotides from the 3' end of the siRNA, resulting in gene-specific knockdown (46,54,56). 
Recently, the RNAi technology has been considered as one of the greatest 
accomplishments for the future decades and several variants of regulatory RNAs can be used 
(50). Among these methods are the small interfering RNAs (siRNAs) (Figure 12A), short 
hairpin RNAs (shRNAs), endogenous or artificial micro RNAs (miRNAs) and bi-functional 
shRNAs (Figure 12B). These interfering RNA variants allow the conserved cellular pathway of 
RNAi which leads to specific hybridization to the mRNA target and to following degradation or 
translational repression (47,48). 
 
Figure 12 - Variants of RNA interference pathways of diferent interfering RNAs: siRNA and bi-functional 
shRNA. A) The siRNA strategy starts with cleavage of long dsRNA by the Dicer enzyme complex into siRNA. 
Such siRNAs are incorporated into a complex where is present the AGO2 and the RISC. Then, AGO2 cleaves 
the passenger strand so that active RISC containing the guide strand is produced. This mRNA strand 
recognizes target sites, resulting in mRNA cleavage. B) The bi-functional concept is to design two shRNAs for 
each targeted mRNA; one with perfect match and other with mismatches. The purpose of the bi-functional 
design is to promote loading of mature shRNAs onto both cleavage-dependent and cleavage-independent 
RISCs, for a more efficient knockdown of target mRNA, through mRNA degradation and also via 
translational repression. AGO2, Argonaute 2; RISC, RNA-induced Silencing Complex; siRNA, small interfering 
RNA; shRNA, short hairpin RNA. Adapted from (48,57). 
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Some years ago the RNAi technology was considered a remarkable tool in cultured 
mammalian cells, since siRNAs can selectively suppress gene expression without evidence of 
non-specific responses, like interferon (47). Nevertheless, owing to the transient nature of the 
synthetic siRNAs, the activation of the interference mechanism is limited because mammalian 
cells lose the amplification machinery, which triggers and keeps the gene silencing in 
Caenorhabditis elegans and Drosophila. Thus, using siRNAs the silencing of gene expression 
only lasts a short period no longer than one week (47). However, in 2002, short hairpin 
interfering RNAs (shRNAs) expressed from RNA polymerase III promoters were constructed by 
several researchers and the gene expression was suppressed for a longer period of time. 
Thus, this drawback was successfully crossed over (47). 
4.1. Short hairpin interfering RNA strategy 
After the breakthrough of siRNAs, vectors engineered to express shRNAs emerged to 
mediate a long-lasting gene silencing. The target gene silencing occurs after stable 
transfection of target cells by shRNA expression cassette (SEC) into the host genome, which 
can be reached by retroviral, lentiviral or adenoviral vectors (47). The producing short hairpin 
RNA vectors process shRNAs in vivo into siRNA-like molecules able to origin gene-specific 
down-regulation. For this purpose, potential target sites within the gene of interest must be 
identified, so that the corresponding oligonucleotides can be designed for shRNA generation 
(46,58). The shRNA oligonucleotide design starts with the selection of a region of 19 
nucleotides into the target gene. The candidate sequence ought not to be within the first 75 
bases, since the nearby start codon regions may have several regulatory protein binding sites. 
The untranslated regions (UTRs) and the consecutive run of three or more thymidine residues 
must also be avoided; the first because UTR-binding proteins and/or translation initiation 
complexes may interfere with binding of the RISC and the second due to a possible premature 
transcription termination. Furthermore, the guanine-citosine content should be considered, 
ensuring that it is around 40%-60% and the secondary structure of oligonucleotides should be 
checked too, because it can interfere in the annealing. Finally, it is very important to align 
some candidate sequences against a suited genome database to verify if there is no 
homology to other genes (50,59,60).  
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An usual shRNA oligonucleotide has five bases for the restriction site at the 5' end and 
one for restriction at the 3' end, 19 bases of sense strand and other 19 of antisense strand. 
Accordingly, the shRNA contains a perfect double stranded with one of them identical to the 
target mRNA and another ensuring proper orientation for correct hairpin loop formation. The 
hairpin loop sequence is composed by 7 to 9 bases linking both strands, in which the most 
effective is 5’-TTCAAGAGA-3’. After that, there are 6 bases of terminator and, eventually, 
other 6 of a unique restriction site, which allows the restriction digestion analysis to confirm 
the presence of the cloned insert (Figure 13). Thereby, the result is an oligonucleotide of 63 
three to 65 basepairs (46,47,61,62).  
 
Figure 13 - Schematic representation of a shRNA oligonucleotide. Firstly, the DNA target sequence is 
chosen. Next, the designed oligonucleotide is inserted into the vector, which is delivered into the host cell. 
The shRNA is transcribed and folds into a loop structure. RE1/2, restriction enzyme 1 and 2; shRNA, short 
hairpin RNA. Adapted from (63). 
Once complete the construction, the vectors contain a DNA sequence that encodes 
the shRNA cloned between a Polymerase III promoter, like the human U6 promoter, and the 
transcription termination site. These vectors represent a definite improvement in initiating 
RNAi, as they use the cell's RNA polymerase III enzyme to transcribe the previously designed 
shRNA. The human U6 promoter provides high levels of expression in numerous cell types, 
resulting in target gene knockdown (64). 
The transcript is terminated at position 2 of the terminator and folds subsequently 
into a loop structure with 3’ overhangs. The shRNA terminations are processed in vivo, 
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converting it into twenty one nucleotides siRNA-like molecules, which in turn trigger the RNA 
interference (65). 
4.2. shRNA mechanism 
To be successful, the shRNAs are designed to follow the rules defined by the details of 
the cellular machinery and are probably processed in the same way to the microRNA 
maturation pathways. Thus, studies on the synthesis and maturation of miRNAs have 
provided the background for shRNA synthesis (48,58,66). Once shRNA expression vector 
introduced into the cell cytoplasm (Figure 14A), it is transported to the nucleus for specific 
shRNA synthesis. Further, the shRNA is processed and transported to the cytoplasm and 
finally incorporated into the RISC for interference, as will be described below (48,64).  
In the nucleus of transfected cells, the shRNA can be transcribed by either RNA 
polymerase II or III (Pol II or III), through RNA polymerase II or III promoters on the shRNA 
expression cassette (SEC), respectively (48,50). As a result, the generated primary transcript 
(pri-shRNA) includes a hairpin loop structure (Figure 14B), which is processed by a complex 
formed by RNAse III endonuclease enzyme Drosha and double-stranded RNA-binding domain 
protein DGCR8 (DiGeorge syndrome critical region gene 8; Figure 13). Such complex measures 
the hairpin and accurately processes the long primary transcripts into pre-shRNAs (Figure 
14C) which are individual shRNAs with two nucleotides 3’ overhang (48,67). Subsequently, 
the pre-shRNA is transported to the cytoplasm by the carrier protein exportin 5 through a Ras 
related GTPase (Ran), followed by loading on the RNAse III complex endonuclease Dicer, TRBP 
(Tat-RNA-binding protein) and PACT (PKR activating protein) (Figure 14D). Such complex 
removes the hairpin to origin the mature shRNA (Figure 14E), which is composed by a double-
stranded siRNA with two nucleotides 3’ overhangs (48).  
Afterwards, the dicer containing complex coordinates the mature shRNA loading on 
the Argonaute 2 protein (Ago-2) containing RISC (Figure 14F), since the pre-shRNA has been 
found to be part of the RISC Loading Complex (RLC), composed of at least Ago-2, dicer and 
TRBP. Such data may mean that pre-shRNA may directly associate with RLC rather than 
through a process of two steps via a different Dicer/TRBP/PACT complex (48). 
Knocking-down LAP1 using the short hairpin RNA strategy 
37 
 
 
Figure 14 - Representation of the shRNA interference strategy and the involved proteins. The shRNA 
expression vector is delivered into the cytoplasm (A) and then to the nucleus for being transcribed. The pri-
shRNA transcripts are processed (B) and form pre-shRNAs (C), which, in turn, are carried out to the 
cytoplasm, to be loaded onto the Dicer/TRBP/PACT complex (D), where they become mature (E). Next, they 
associate with Ago containing RISC (F), providing RNA interference either via mRNA cleavage and 
degradation, or through translational suppression via p-bodies (G). Ago, Argonaute protein; DGCR8, 
DiGeorge syndrome critical region gene 8; Pri-shRNA, primary shRNA; PACT, PKR activating protein; RISC, 
RNA-induced Silencing Complex; TRBP, Tat-RNA-binding protein (48). 
 
After loading onto RLC and passenger strand departure, both shRNA and siRNA should 
behave equally in the RISC (68). The major component of this complex is the Argonaute family 
of proteins, of which only Ago-2 exhibits endonuclease activity to cleave the shRNA into a 
single-stranded stem. Other argonaute proteins also belong to RISC, despite lack of 
identifiable endonuclease activity. The Ago-2 protein cleaves mRNA to start its degradation, 
while other Argonaute proteins without endonucleolytic activity bind to partially 
complementary target sites located at the 3’ UTR for translation repression, in processing 
bodies (p-bodies). Such mechanism in p-bodies is still not totally known, but it is thought to 
be processed through target mRNA sequestration and deadenylation, leading to its 
destabilization. Thus, the target mRNA is either cleaved or conformationally changed (Figure 
14G) following which both types of structures are direct to p-bodies (48).  
A 
B 
C 
D 
E 
F 
G 
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In conclusion, mature shRNA in the Dicer/TRBP/PACT complex are associated with 
Ago-2 containing RISC and provide RNAi either through mRNA cleavage and degradation, or 
through translational suppression via p-bodies (48).  
4.3. Applications of RNAi and shRNA Benefits 
RNAi has been evolving over the years as a powerful tool for identification of specific 
targets for several diseases therapy. In addition to research of novel ways for clinical 
treatments, this technique has also been used to analyze gene function, to recognize and 
eliminate invading parasites and to create model systems, through quick and simple 
generation of loss-of-function phenotypes (47,50). For instance, some studies have shown 
that it is possible to silence a neuron-specific gene in a model system for neuronal 
differentiation, which may point out to a possible application of RNAi in neurogenesis and 
differentiation studies in mammalians (58). 
Indeed, the shRNA producing vectors are the most suitable to human disorders 
treatment, specifically to reduce or even abolish the abnormal gene expression typical of 
some diseases, for example, the spinocerebellar ataxia type one, amyotrophic lateral sclerosis 
and Alzheimer disease (51). Such antisense shRNAs have the potential to selectively 
knockdown specific cancer targets, allowing an effective personalized treatment, improving 
the conventional therapies (48). Additionally, this therapeutics  useful to attenuate viral and 
parasite infections, at least in vitro, for example hepatitis B and C viruses (HBV and HCV) and 
human immunodeficiency virus (HIV). Moreover, shRNA strategy was already approved for 
clinical trial by Food and Drug Administration (FDA) in treating human hepatitis and, more 
recently, anti-HIV therapies based on RNAi have also been used (50). The effectiveness of this 
therapeutic method is determined in part by intracellular availability of interfering RNAs, so 
the current goals are mostly related to development of systems and vectors, for transporting 
great amounts of dsRNA to the target tissue or organ (51). Normally, the most used vectors 
are viral because of their high transfection rate and effective integration of exogenous DNA. It 
is actually important the optimization of shRNA constructs for obtaining powerful and long-
lasting effects using few copies of shRNA, since it can be continuously produced by the host 
cell. It is believed that less than five copies of shRNA integrated in host genome are enough to 
achieve an effective gene knockdown, whereas additional copies are required in siRNA 
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approach. Thus, such difference in copy numbers may result in less off-target effects in shRNA 
strategy, which can also be explained by the endogenous processing and nuclear regulation, 
after the transcription of shRNAs. Therefore, the siRNA method is more susceptible to 
degradation in cytoplasm, which provides a higher probability of off-target silencing (48,69).  
RNAi therapy has been shown to be well tolerated in several animal models, allowing 
the transition into the medical field. So, further investigation of the features and limitations 
of such techniques is crucial before large-scale applications become routine (48,50). For 
example, in vitro data have shown that the introduction of both synthetic siRNA and shRNA 
oligomers can trigger a partial interferon response, because the insertion of dsRNA more than 
about thirty basepairs into mammalian cells may result in activation of a similar pathway to 
the mechanism against viral infection, which can result in overall degradation of mRNA and 
thus broad inhibition of translation (48,70,71). 
Even so, the ability of this valuable tool of reducing gene expression marks a major 
biomedical advance in the development of human disease therapies, mostly for dominantly 
inherited disorders (50), such as the early onset torsion dystonia already addressed in this 
work. 
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RNA interference approaches represent powerful strategies for unraveling putative 
gene functions in mammalian cells. Since the function of LAP1 remains poorly understood, we 
induced the knockdown of huLAP1 through the short hairpin RNA interference strategy - in 
order to mimic the cellular behavior in the absence of huLAP1. It is thought that LAP1 plays a 
role in the maintenance of the NE architecture by binding to lamins and chromosomes, but 
this is not well described. 
Additionally, LAP1 is an interacting partner of the torsinA protein, the mutated 
protein in DYT1 dystonia, and can recruit torsinA to the NE. Thus, huLAP1 may also be 
involved in the physiological/pathological torsinA pathway. Therefore, it is believed that LAP1 
can have a high relevance in biomedical field and more studies would be surely required to 
determine its specific function. 
 
The specific goals of this dissertation are the following: 
 To generate LAP1 shRNA constructs using the pSIREN-retroQ vector; 
 To establish the SH-SY5Y cells transfection conditions for both LAP1 shRNA 
constructs; 
 To determine the effects of huLAP1 knockdown using biochemical assays; 
 To evaluate the effects of huLAP1 knockdown in cellular integrity by microscopy 
analysis. 
 
 
 
 
 
 
The methodology carried out in this work was mostly based on “Knockout™ RNAi 
Systems” protocol of Clontech (Catalogue No. 631528). 
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RNA INTERFERENCE - shRNA STRATEGY 
5. shRNA SEQUENCE DESIGN 
The effectiveness of shRNA methodology in the knockdown approach depends on 
choosing the proper target sequence within the gene of interest (TOR1AIP1) and the suitable 
design of oligonucleotides to generate the shRNA. 
5.1. Selection of target sequences 
Two regions of 19 nucleotides of the TOR1AIP1 sequence (NM_001267578.1) were 
chosen according to some criteria. The sequences within 5’ and 3’ untranslated regions and 
nearby regions of the start codon (within 75 bases) could not be selected, since they may 
have regulatory protein binding sites which may interfere with the binding of the interfering 
RISC. The target sequences that contain a consecutive run of 3 or more T residues were also 
avoided, because it can cause premature termination of the transcript.  
Additionally, the GC content of the 19 nucleotides should also be calculated, being 
around 40% and 60%. The selection of the candidate sequences was made according to 
criteria mentioned above, through the Clontech designer tool (Figure 15), available on 
http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesignInit.do.  
  
Figure 15 - Clontech RNAi target sequence selector. The TOR1AIP1 sequence was introduced to obtain 
potential target sequences (http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesignInit.do). 
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As a result, 20 candidate target sequences were obtained and blast searches were 
performed through http://blast.ncbi.nlm.nih.gov/Blast.cgi. Such tool yielded the comparison 
between the candidate sequences and genome database to identify specific target sequences 
within the gene of interest with no significant homology to additional genes. Therefore, two 
distinct shRNA target sequences were properly selected. 
5.2. Oligonucleotides design 
A synthesis of two complementary oligonucleotides was required, a top strand and a 
complementary bottom strand, for each shRNA target sequence. For this purpose, inserting 
the selected target sequence into the online designer tool of Clontech, available on 
http://bioinfo.clontech.com/rnaidesigner/oligoDesigner.do, the oligonucleotides were 
properly designed (Figure 16).  
 
Figure 16 - Designing of oligonucleotides through the shRNA sequence designer (Clontech). The selected 
target sequence is inserted (black arrow) in shRNA sequence designer tool and then the complementary 
oligonucleotide pair is properly designed (purple arrow). 
The designed sequences were highly purified, ensuring a higher percentage of full-
length nucleotides, which allowed the cloning of the complete and functional insert.  
The sequences of the oligonucleotides included: 
 Restriction sites that enable directional cloning of the oligonucleotides into the 
vector: the BamH I restriction site overhang on the 5’ top strand and the EcoR I 
restriction site overhang on the 5’ bottom strand;  
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 A target sense sequence with 19 nucleotides;  
 A 7-9 nucleotide hairpin loop sequence, normally the 5'-TTCAAGAGA- 3' sequence; 
 A target antisense sequence with 19 nucleotides; 
 A RNA Pol III terminator sequence, which consists of a 5 or 6 thymidine residues; 
 A unique restriction site (Mlu I), downstream of the terminator sequence, for 
restriction digest analysis to verify the presence of the shRNA oligonucleotides 
into the RNAi-Ready pSIREN-RetroQ Vector after the ligation; 
 One base for the restriction site at the 3' end (when digested with EcoR I). 
These oligonucleotides were commercially synthesized by Nzytech. 
6. CLONING INTO RNAi-READY pSIREN-RETROQ VECTOR 
The Knockout RNAi System from Clontech includes the RNAi-Ready pSIREN-RetroQ 
vector (see appendix) that uses the cell's own Pol III to transcribe a designed shRNA, using the 
human U6 promoter. Retroviral infection allowed the introduction of shRNA into the cell with 
high efficiency and moderate shRNA expression. Two different oligonucleotides were selected 
and further cloned, in order to interfere with two different regions of the huLAP1B, further 
mentioned. Thus, each respective top and bottom strands of the oligonucleotide were 
annealed and then ligated into the vector. The same procedure was followed for a negative 
control missense oligonucleotide. 
6.1. shRNA oligonucleotides annealing 
Each oligonucleotide (Nzytech) was ressuspended in TE buffer to a concentration of 
100 μM. Next, the oligonucleotides were mixed at 1:1 ratio (10 μL + 10 μL), which resulted in 
50 μM of each double-stranded oligonucleotide (assuming 100% of annealing). Then, the 
mixture was added to the thermal cycler (Mastercycler personal, Eppendorf): 
 Heat at 95°C for 30 seconds (to disrupt the hairpin and promote the 
intermolecular annealing); 
 Heat at 72°C for 2 minutes; 
 Heat at 37°C for 2 minutes; 
 Heat at 25°C for 2 minutes 
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The mix was stored at -20°C until the ligation was performed. 
6.2. Ligation of oligonucleotides into pSIREN vector  
The pSIREN-RetroQ vector was previously digested with EcoR I and BamH I restriction 
endonucleases (New England Biolabs - NEB). The annealed oligonucleotides were diluted with 
TE buffer to a concentration of 0,5 µM. Therefore we ensured that they were in appropriate 
amount to perform ligation with good efficiency. Subsequently, a ligation reaction for each of 
two oligonucleotides was assembled. 
For each ligation (20 μL), the following reagents (Clontech) were mixed in a microtube: 
 13,75 μL of nuclease-free H2O;  
 2 μL of 10X T4 DNA Ligase Buffer; 
 1,25 μL of linearized pSIREN vector (20 ng/μL); 
 2 μl of diluted, annealed oligonucleotide (0,5 μM); 
 1 μL of 10X shRNA Ligation Enzyme Mix (10 mg/mL). 
It was also made a ligation using a negative control shRNA annealed oligonucleotide 
(Nzytech), simultaneously. The reaction mixture was incubated during 3 hours at room 
temperature to perform the ligation (Figure 17) and then stored at -20°C until the 
transformation has been performed. 
 
Figure 17 - Schematic representation of the ligation of the oligonucleotide to pSIREN-retroQ vector. RNAi-
Ready pSIREN-RetroQ is provided as a linearized vector designed to express a short hairpin RNA (shRNA) 
and is digested with BamH I and EcoR I. 
Knocking-down LAP1 using the short hairpin RNA strategy 
51 
 
6.3. Bacterial transformation and DNA isolation  
After the ligations, bacteria cells were transformed with the pSIREN-retroQ constructs 
in order to obtain high yields of plasmid DNA for further isolation. 
6.3.1. Transformation of E.coli XL1-Blue 
Subsequently, 50 µL of E.coli XL1-Blue competent cells were thawed on ice and 5 µL of 
each DNA ligation were added to cells. Then, the microtube was incubated on ice during 20 
minutes, followed by a thermal shock at 42°C in water bath for 70 seconds. Next, the 
microtubes were placed on ice again for 2 minutes and, subsequently, 450 µL of SOC medium 
(see appendix) was added to each tube. The microtubes were incubated at 37°C for 60 
minutes with shaking at 170 rpm. After that, the culture was centrifuged at 14000 rpm during 
1 minute and the supernatant was discarded. The pellet of cells was ressuspended in the 
remaining liquid and spread on the LB/ampicilin plates, which were incubated at 37°C for 16 
hours, until the arising of colonies. Control transformations were also performed 
simultaneously. These included a negative control transformation of vector without DNA. 
6.3.2. Extraction of plasmid DNA - alkaline lysis method 
A single colony was inoculated into a test-tube with 3 mL of LB medium/ampicilin and 
then incubated at 37°C overnight with shaking at 170 rpm. Subsequently, 1.5mL of the culture 
was poured to a microtube, followed by a centrifugation at 14000 rpm during 90 seconds (all 
centrifugations were performed at 4°C). The supernatant was discarded and the pellet was 
ressuspended in 100 L of solution I (see appendix) and mixed by vortexing. Then, it was 
added 200 L of solution II (see appendix) and mixed through five gentle inversions, placing it 
on ice immediately. Lastly, 150 L of solution III (see appendix) was mixed by ten careful 
inversions. The mixture was then incubated 5 minutes on ice and, next, a centrifugation was 
performed during 10 minutes (14000 rpm). The clear supernatant was transferred to a new 
microtube and 2.5 volumes of ethanol 100% were added in order to precipitate the DNA.After 
incubation at -20°C during 1 hour, samples were centrifuged for 20 min at 14000 rpm and 
4°C. The supernatants were discarded and the pellets rinsed with 750 μL of 70% ethanol, and 
then samples were incubated for 5 minutes at -20°C before new centrifugation for 5 minutes 
at 14000 rpm and 4°C.  After discarding the supernatant, the pellet dried at 37°C for 1 hour 
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and then was ressuspended with 50 L of water with RNAse (20 μg/mL). The DNA was 
conserved at -20°C until the accomplishment of a restriction analysis. 
6.3.3. DNA restriction and electrophoretic analysis 
A restriction analysis of plasmid DNA was performed to figure out if the pretended 
DNA oligonucleotides were efficiently cloned. 
For DNA restriction, the reaction was made according to manufacturer’s instructions, 
with the following reagents (NEB): 
 Buffer 10X (NEB buffer 3); 
 BSA 100X; 
 1 L of Mlu I restriction enzyme (10 U/L); 
 1 L of Sal I restriction enzyme (20 U/L). 
The mix solution was completed with distilled water to achieve the volume of 20 L. 
Once the mix reaction was ready, 10 L of the mix reaction was added per 2 L of DNA into a 
microtube. Finally, the samples were incubated at 37°C during 2 hours for enzymatic 
digestion, before further analysis by electrophoresis. The required amount of agarose (0,8% 
gel) was weighed and dissolved with 1X TAE buffer. The agarose was heated until dissolved 
and homogenized. The electrophoresis apparatus (Bio-Rad) was prepared and the comb was 
correctly placed. The agarose solution was allowed to cool to 60°C and then the ethidium 
bromide (0,5 g/mL) was added and gently mixed. The gel was poured into the gel tray until 
polymerization. The appropriate amount of 6X Loading Buffer (LB) was added to the DNA 
samples. Distilled water was added to make up the volume, when appropriate. The gel was 
placed into the electrophoresis tank, covered with 1X TAE (see appendix) and the comb was 
removed carefully. Then, DNA marker (DNA 1 Kb Plus Ladder, Invitrogen) was loaded into the 
gel as well as the DNA samples. The gel run approximately 50 minutes at 100 Volts. The gel 
was visualized and analysed in an ultraviolet light transilluminator (AlphaImager® HP System, 
Alpha Innotech) and photographs were taken. 
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6.4. DNA sequencing 
The DNA samples were purified and amplified by PCR for further sequencing to 
confirm the presence and sequence of the oligonucleotides. 
6.4.1. DNA purification with column QIAquick 
Five volumes of PB buffer (Qiagen) were added to each DNA sample and mixed by 
vortexing. The mixture was transferred to a QIAquick column (Qiagen) and then a 
centrifugation was made at 14000 rpm during 1 minute. The supernatant was discarded 
followed by addition of 750 μL of PE buffer (Qiagen) to the column. After that, another 
centrifugation of 1 minute was performed (14000 rpm) and the filtrate was discarded. The 
column was inserted into a new tube and 50 μL of Milli-Q water was added into the center of 
the column. A last centrifugation of 1 minute (14000 rpm) was made to elute the DNA that 
was further stored at -20°C. 
6.4.2. PCR sequencing 
A PCR reaction was assembled for each ligation mixture, by combining the following 
reagents in a PCR tube: 
 1,5 μL of 10X U6 Forward Sequencing Primer (Clontech - see appendix); 
 4 μL of Sequencing Mix (composed of dye terminators, deoxynucleoside 
triphosphates, ampliTaq DNA polymerase, FS, rTth pyrophosphatase, magnesium 
chloride and buffer) (Applied Biosystems); 
 4 μL of purified DNA. 
The mix solution was made up with distilled water to achieve the volume of 20 L. 
The samples were well mixed and placed into the thermal cycler, using the following 
program: 
 Heat at 96°C for  1 minute; 
25 cycles of: 
 96°C for  30 seconds; 
 42°C for 15 seconds;  
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 60°C for 4 minutes. 
The samples were purified after PCR by ethanol and sodium acetate precipitation. 
6.4.3. Precipitation of amplified DNA 
After the PCR, the samples were transferred to microtubes and 2,5 volumes of 
ethanol 100% were added, followed by addition of 1/10 of 3M sodium acetate (pH = 5.2) to 
each sample. They precipitated on ice during 30 minutes. After that, a centrifugation at 13000 
rpm of 20 minutes (4°C) was performed. The supernatant was discarded and 250 μL of 
ethanol 70% was also added. It was stored 5 minutes at -20°C and then another 
centrifugation was made at 13000 rpm of 5 minutes (4°C). The supernatant was discarded 
and the pellet dried at 37°C during 1 hour, approximately. The DNA samples were sequenced 
using an automated DNA sequencer (ABI PRISM 310, Applied Biosystems). 
6.5. DNA isolation and purification 
The E. coli bacteria were transformed, as described previously, with the recombinant 
DNA and subsequently isolated and purified through “Maxiprep DNA Purification System” 
(Promega) to obtain higher amounts of DNA. 
6.5.1. Maxiprep DNA purification system 
Once the E.coli transformation, a pre-culture of a single colony was performed as 
previously and then 1 mL of each culture was transferred to 1L of LB medium with ampicilin 
(50 g/µL). The culture was incubated overnight at 37°C with shaking at 170 rpm. Later, each 
culture was divided into four 250 mL tubes and centrifuged at 4,000 g for 15 minutes. The 
supernatants were discarded and the pellets ressuspended in 30 mL of Ressuspension 
Solution (see appendix). Then, 30 mL of Lysis Solution (see appendix) was added and mixed by 
gently invertions until the solution becomes clear and viscous. Then, 30 mL of Neutralization 
Solution (see appendix) were also added and carefully inverted. Next, a centrifugation was 
performed at 15000 g during 15 minutes (slow deceleration). Each supernatant was 
transferred to a new 250 mL tube. Then, 0.5 volume of isopropanol was added, followed by a 
centrifugation of 15000 g for 15 minutes (slow deceleration). The supernatant was discarded 
and the DNA pellet was ressuspended in 4 mL of Milli-Q water. After that, 15 mL of Wizard 
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Maxipreps DNA Purification Resin (Promega) were added to DNA solution. Next, the mix 
resin/DNA was transferred to a PureYield™ Maxi Binding Column (Promega) and vacuum was 
applied. The column was washed with 25 mL of Column Wash Solution (see appendix) and 
vacuum was again applied. This step was repeated twice. Then, 10 mL of ethanol 80% was 
added to the column and vacuum was again turned on. The column was assembled into a 50 
mL tube and a centrifuged at 1300 g during 5 minutes. The supernatant was discarded and 
the column was placed into the vacuum system to dry. The column was then placed into a 
new 50 mL tube and 3 mL of 65°C pre-heated nuclease-free water was added. After 1 minute, 
the DNA was eluted through two centrifugations at 1300 g during 5 minutes each. 
6.5.2. DNA precipitation and concentration measurement 
After DNA isolation by Maxiprep system, the samples were transferred to microtubes 
and 2,5 volumes of ethanol 100% were added, followed by addition of 1/10 of 3M sodium 
acetate (pH = 5.2) for each sample and let to precipitate at -20° overnight. Later, a 
centrifugation at 13000 rpm of 20 minutes (4°C) was performed. The supernatant was 
discarded and 700 μL of ethanol 70% was also added. It was stored 5 minutes on ice and then 
another centrifugation was made. The supernatant was discarded and the pellet dried at 37°C 
during 1 hour, approximately. The pellet was ressuspended in 50 L of Milli-Q water. The DNA 
concentration and the purity ratio (260/280 nm) were measured on a NanoDrop 
Spectrophotometer ND-1000 (Thermo Scientific). The DNA samples were conserved at -20°C. 
7. CELL CULTURE 
SH-SY5Y human neuroblastoma cells are derived from the cell line SK-N-SH (ATCC, 
Barcelona, Spain; CLR-2266), from a bone marrow biopsy of neuroblastoma patients. The cells 
were grown in Minimal Essential Medium (MEM):F12 (1:1), supplemented with 10% Fetal 
Bovine Serum (FBS) with 2 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin 
(Antibiotic/antimycotic (AAs, Gibco) - complete SH-SY5Y cell medium. Cultures were 
maintained at 37°C and 5% CO2 and were subcultured whenever they achieved 90-95% of 
confluence. 
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7.1. Resazurin cell viability assay 
The resazurin viability assay is a fluorescence assay that detects metabolic activity in 
cells. The blue nonfluorescent resazurin reagent is reduced to highly fluorescent resorufin 
(pink colour) by dehydrogenase enzymes in metabolically active cells. This conversion only 
occurs in viable cells and, thus, the amount of resorufin produced is proportional to the 
number of viable cells in the sample. The resorufin formed in the assay can be quantified by 
measuring the relative fluorescence units.  
It was added 10% of resazurin/SDS% solution to SH-SY5Y cell medium (1 mL) and the 
plate was shaken. The plates were incubated at 37°C during 4 hours. Then, the cell medium 
was removed and the absorbance was measured through 570 and 600 nm, using the Infinite 
M200 (Tecan). 
7.2.  Transient transfection with shRNA constructs 
7.2.1. Transient transfection using Lipofectamine 2000TM 
According to the manufacturer’s protocol (Invitrogen), Lipofectamine 2000TM 
transfection reagent is a cationic liposome which forms a complex with negatively charged 
DNA molecules to overcome the electrostatic repulsion of the cell membrane. The complexes 
are thought to deliver nucleic acids through endosomes after endocytosis of the complex, 
although the exact mechanism for gene transfection mediated by cationic liposomes is still 
unclear (Figure 18). 
 
Figure 18 - Mechanism of action of Lipofectamine 2000
TM
 transfection reagent. Lipofectamine is a cationic 
liposome based reagent that functions by complexing with nucleic acids, allowing them to overcome the 
electrostatic repulsion of the cell membrane and to be endocytosed. Adapted from Invitrogen. 
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SH-SY5Y human neuroblastoma cells were grown in 6-well plates at a density of 2,0 x 
106 of cells per plate, using complete SH-SY5Y cell medium until 90% of confluence. The DNA 
(2 µg and 5 µg) and Lipofectamine 2000TM (Invitrogen) were each diluted in SH-SY5Y serum- 
and AAs-free medium and incubated for 5 minutes at room temperature (1 µg of DNA to 2 µg 
of Lipofectamine). Then, the DNA solution was added to the diluted Lipofectamine tubes, 
drop by drop, followed by gentle mixing with the micropipette. In order to form the DNA-lipid 
complexes, the tube was allowed to rest for 20 minutes at room temperature. Afterwards, 
the solution was carefully added, drop by drop, into the 6-well plates containing AAs-free 
medium. Cells were incubated at 37°C and 5% CO2. The cell medium was replaced 6 hours 
after transfection and cells further incubated at 37°C and 5% CO2 for 24 hours and 48 hours. 
At these time points, cells were harvested by adding boiling 1% SDS. The cell lysates were 
then boiled (10 min), sonicated (10 seconds) and stored at -20°C for further using. 
7.2.2. Transient transfection of SH-SY5Y using TurboFect™ 
According to the manufacturer’s protocol (Thermo Scientific), the TurboFect™ 
Transfection Reagent is a sterile solution of a proprietary cationic polymer in water, which 
interacts with DNA. Such polymer forms positively-charged, stable and highly diffusible 
complexes that are endocytosed. The “proton-sponge” effect of TurboFect™ buffers 
endosomal pH by provoking massive proton accumulation and passive chloride influx. Rapid 
osmotic swelling causes endosomal rupture, allowing translocation of DNA to the nucleus 
(Figure 19). These complexes protect DNA from degradation and facilitate efficient plasmid 
delivery into cells. 
 
Figure 19 - Mechanism of action of TurboFect transfection reagent. TurboFect is an efficient, easy-to-use, 
non-immunogenic transfection reagent to deliver DNA plasmids and expression vectors into eukaryotic cells 
(Thermo Scientific). 
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SH-SY5Y cells were grown in 6-well plates at a density of 2,0 x 106 of cells per plate, 
using complete medium until 90% of confluence. Each amount of DNA (2 µg or 5 µg) was 
diluted in serum- and AAs-free medium. The TurboFectTM Transfection Reagent (Thermo 
Scientific) was vortexed and then added to the diluted DNA in a 1:1 proportion. The mixture 
were mixed by vortexing and rested for 20 minutes at room temperature for complexes 
formation, while the culture medium was replaced for AAs-free medium. Afterwards, the 
solution was carefully added, drop by drop, into the 6-well plates containing the cell medium. 
The cells were incubated at 37°C and 5% CO2. The cell medium was replaced 6 hours after 
transfection and cells further incubated at 37°C and 5% CO2 for 24 hours and 48 hours. At this 
time points cells were harvested by adding boiling 1% SDS or fixed using 4% 
paraformaldehyde for immunocytochemical analysis. 
8.  BCA PROTEIN CONCENTRATION ASSAY 
The total concentration of proteins was measured through the BCA protein assay, in 
which the proteins reduce the Cu2+ to Cu+, obtaining an alkaline purple-coloured solution 
(biuret reaction), detected by BCA reagent (Bicinchoninic Acid) of Pierce® BCA Protein Assay 
Kit (Thermo Scientific). The protein standards composition is described on Table 1. 
Table 1 - Standard preparations used in BCA protein assay. BSA, Bovine Serum Albumine; SDS, Sodium 
Dodecyl Sulfate; WR, Working Reagent. 
Standards BSA (µL) 1% SDS (µL) Protein Mass (µg) WR (µL) 
P0 - 25 0 200 
P1 1 24 2 200 
P2 2 23 4 200 
P3 5 20 10 200 
P4 10 15 20 200 
P5 20 5 40 200 
 
The protein samples were diluted in 1% SDS (2,5 µL of protein in 22,5 µL of 1% SDS). 
The Working Reagent (WR) was prepared by combining BCA reagent A with BCA reagent B 
(50:1 proportion). Then, 200 µL of WR was added to each well, followed by incubation at 37°C 
for 30 minutes. The microplate cooled at room temperature and then the absorbance was 
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measured at 562 nm, using the Infinite M200 (Tecan) and I-controlTM software. A standard 
curve was obtained by plotting BSA standard absorbances vs BSA concentrations and, 
therefore, it was used to calculate the total protein concentration of each sample. 
Duplicates of samples and standards were always prepared. 
9.  SDS-POLYACRILAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
After the determination of the total protein concentration, the proteins were 
separated using SDS-PAGE. The SDS - Polyacrylamide gel electrophoresis consists in a 
technique which allows the electrophoresis of proteins on a polyacrylamide gel in order to 
separate them, according to their molecular weight. A 10% polyacrilamide running gel and a 
3,5% stacking gel (see appendix) were prepared to visualize the huLAP1B and huLAP1C 
proteins, with 68 kDa and 55 kDa, respectively. Once the gels polymerized, the samples were 
prepared, by the addition of ¼ volume of loading buffer (LB) and boiled for 10 minutes. The 
used protein marker was the “Precision Plus Protein™ Dual Color Standards” (Bio-Rad). The 
gel ran at 90mA for approximately 4 hours. Subsequently, the proteins were transferred to a 
nitrocellulose membrane (GE Healthcare Life Sciences) at 200 mA, during approximately 18 
hours. 
10.  IMMUNOBLOTTING 
Ponceau S staining of proteins bands has been applied to assess equal gel loading. 
This loading control practice has been described as a fast, inexpensive and nontoxic method, 
and binding is fully reversible in a few minutes. The nitrocellulose membranes were incubated 
in Ponceau S solution for 7 minutes, followed by a brief rinse in distilled water. The 
membranes were then scanned in a GS-800 calibrated imaging densitometer (Bio-Rad). After 
that, membranes were washed in 1X TBST for 2–3 minutes with gentle agitation and 1X in 
distilled water until the staining was completely eliminated.  
10.1. Membranes incubation 
First, the membranes were hydrated in 1X TBS for 5 minutes and then soaked in 5% 
low fat milk/1X TBST, with shaking, for blocking the unspecific binding sites (normally for 1 
hour, depending on the primary antibody). Once blocked, the membrane was incubated with 
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primary antibody diluted in 3% BSA/1X TBST or 3% low fat milk/1X TBST, depending on the 
antibody. The specifications for the used primary antibodies are described on the following 
Table 2. 
Table 2 - Primary antibodies used in the immunoblotting procedure. LAP1,Lamina-Associated Polypeptide 
1; ON, overnight; PARP, Poly (ADP-Ribose) Polymerase. 
Primary antibody 
Expected 
labeling 
Dilution 
Dilution 
solution 
Time of 
incubation 
Provider 
Rabbit anti-LAP1 
LAP1  
(55kDa, 
68kDa) 
1:20000 
3% BSA/1X 
TBST 
4 hours with 
shaking and 
left ON 
Kindly provided 
by Dr. William 
T. Dauer 
Mouse anti-acetylated α-
tubulin  
α-acetylated 
tubulin 
(≈50 kDa) 
1:1000 
3% low fat 
milk/1X TBST 
2 hours with 
shaking 
Sigma 
Rabbit anti-cleaved PARP 
(214/215) cleavage site 
specific polyclonal antibody 
Cleaved 
PARP  
(85 kDa) 
1:1000 
3% BSA/1X 
TBST 
3 hours with 
shaking 
Millipore 
Rabbit anti-Lamin B1 
(H-90) 
Lamin B1  
(67k Da) 
1:1000 
3% BSA/1X 
TBST 
4 hours with 
shaking and 
left ON 
Santa Cruz 
Biotechnology 
 
Subsequently, the membranes were washed three times for 10 minutes in 1X TBST. 
After that, they were incubated with secondary antibody, according with primary antibody’s 
specificity (Table 3). The membrane was washed three times for 10 minutes with 1X TBST. 
Table 3 - Secondary antibodies used in the immunoblotting procedure. ECL, Enhanced Chemiluminescence; 
LAP1, Lamina-Associated Polypeptides 1; PARP, Poly (ADP-Ribose) Polymerase. 
Secondary antibody Dilution 
Dilution 
solution 
Time of 
incubation 
Company 
ECL
TM
 Anti-Rabbit IgG, Horseradish 
Peroxidase Linked Whole Antibody 
(from donkey) 
1:5000 
3% Low fat 
milk/1X TBST 
2 hours with 
shaking 
GE Healthcare 
Life Sciences 
ECL
TM
 Anti-Mouse IgG, Horseradish 
Peroxidase Linked Whole Antibody 
(from donkey) 
1:5000 
3% Low fat 
milk/1X TBST 
2 hours with 
shaking 
GE Healthcare 
Life Sciences 
10.2. Immunodetection 
The membrane was incubated for 1 minute with ECLTM (Enhanced 
Chemiluminescence), combining a solution A and a solution B in a 100:1 proportion (GE 
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Healthcare Life Sciences) or, if appropriate, incubating with LuminataTM Crescendo HRP 
Substrate (Millipore) for 5 minutes in a dark room. The ECLTM and LuminataTM Crescendo are 
chemoluminescent non-radiative methods for detection of specific antigens, conjugated 
directly or indirectly with horseradish peroxidase-labelled antibodies. After the X-Ray films 
(Kodak) had been exposed, they were developed and fixed with appropriate solutions. 
Afterwards, the X-ray films were scanned in GS-800 Calibrated Densitometer (Bio-Rad) and 
quantified through the 1-D Analysis Quantity-One software (Bio-Rad). 
11. IMMUNOCYTOCHEMISTRY 
The SH-SY5Y human neuroblastoma cells were grown in glass coverslips, which were 
previously coated with poly-L-ornithine, until a 90% confluency has been reached. 
Afterwards, they were transfected with Lipofectamine 2000TM as previously described. 24 
hours later, the cell medium (free-AAs with serum) was removed and 1 mL of 
paraformaldehyde fixative solution was added to each well for 20 minutes. Next, three 
washes with 1mL of 1X PBS were performed, followed by permeabilization with 0,2 % triton 
X-100 diluted in 1X PBS during 10 minutes. After that, four washes were performed with 1X 
PBS and the blocking solution (3% BSA/1X PBS) was added for 1 hour. The blocking solution 
was removed and, then, the primary antibody was added (Table 4). It was washed again for 
three times with 1X PBS, followed by incubation with the secondary antibody (Table 5). To 
finish, three washes with 1X PBS were performed and the coverslips were mounted on 
microscope glass slides with one drop of mounting medium containing DAPI for nucleic acid 
staining (Vectashield, Vector Laboratories). Photographs were acquired using an inverted 
Olympus IX81 epifluorescence microscope. 
Table 4 - Detailed information about primary antibodies used in immunocytochemistry procedure LAP1, 
Lamina-Associated Polypeptides 1. 
Primary antibody Dilution Time of incubation Company 
Rabbit anti-LAP1 1:4000 1 hour and 30 minutes 
Kindly provided by Dr. 
William T. Dauer 
Mouse anti-acetylated α-tubulin 1:250 1 hour and 30 minutes Sigma 
Rabbit anti-Lamin B1 (H-90) 1:50 2 hours Santa Cruz Biotechnology 
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Table 5 - Detailed information about secondary antibodies used in immunocytochemistry procedure. IgG, 
Immunoglobulin G. 
Secondary antibody Dilution Time of incubation Company 
Alexa Fluor® Goat anti-rabbit 594 IgG (H+L) 1:300 1 hour and 30 minutes Invitrogen 
Alexa Fluor® Goat anti-mouse 488 IgG (H+L) 1:300 1 hour and 30 minutes Invitrogen 
 
12. CONFOCAL MICROSCOPY 
SH-SY5Y cells morphology and cytoskeleton integrity were evaluated through confocal 
microscopy after human LAP1 knockdown. 450 cells were counted per condition: cells 
transfected with the shRNA control, construct 1, construct 2 or construct 1 and 2 together. 
Specifically, the nuclei and the corresponding nuclear envelopes labeled with DAPI and anti-
LAP1 antibody, respectively were counted. 
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Figure 20 - Schematic illustration of the generation of human LAP1B shRNA constructs. huLAP1, human 
Lamina-Associated Polypeptides1; shRNA, short hairpin RNA; TOR1AIP1, Torsin1A-interacting protein 1. 
13. GENERATION OF HUMAN LAP1 shRNA CONSTRUCTS 
The generation of short hairpin RNA (shRNA) constructs for a knockdown approach 
involves three steps: the choice of the proper target sequence within the gene of interest 
(Figure 20A), the oligonucleotide design (Figure 20B) and further cloning into an expression 
vector (Figure 20C). Our gene of interest is the TOR1AIP1 (NM_001267578.1), which encodes 
the human LAP1B protein (NP_001254507.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TARGET SEQUENCE 
SELECTION 
OLIGONUCLEOTIDE  
DESIGN 
CLONING INTO 
pSIREN VECTOR 
Gene of interest 
(TOR1AIP1) 
Candidate target 
sequences 
Two huLAP1B target 
sequences properly 
selected 
Clontech oligonucleotide 
designer 
huLAP1B complementary 
DNA oligonucleotides 
Two oligonucleotides for 
exons 7 and 8 of huLAP1B  
Top  
strand 
Bottom  
strand 
Two oligonucleotides for 
exon 10 of huLAP1B 
Top  
strand 
Bottom  
strand 
further transcribed in 
cell 
A 
 
B 
 
C 
 
Ligation and transformation 
Annealing 
Ligation and transformation 
Annealing 
DNA Isolation 
Knocking-down LAP1 using the short hairpin RNA strategy 
66 
 
13.1. Selection of target sequences 
After the analysis of 20 potential RNAi target sequences for TOR1AIP1 (Figure 21), two 
target sequences of 19 nucleotides were properly selected, according to the criteria 
previously described in Materials and Methods. Briefly, the selection was performed using 
the bioinformatic tool (Clontech designer) and the specificity of shRNAs for huLAP1B was 
tested using the Blast tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The Blast results clearly 
indicated that each selected LAP1B target sequence has 100% homology with our gene of 
interest and no significant homology with additional genes. 
 
Figure 21 - Potential RNAi target sequences for TOR1AIP1 gene. The two selected target sequences were 
the number 9 and 18 (highlighted). The positions of targets in mRNA sequence of TOR1AIP1 (4054 bp) were 
1295 and 2008 bp, respectively. The guanine cytosine content was suitable (47%). Available on 
http://bioinfo.clontech.com/rnaidesigner/sirnaSequenceDesignInit.do. RNAi, RNA interference. 
The first shRNA target sequence (sequence 9) is directed to a region located between 
exon 7 and exon 8 of TOR1AIP1 sequence (1296-1315 bp). The second target sequence 
(sequence 18) is within the exon 10 of TOR1AIP1, located at position 2009-2027 bp (Figure 
22). 
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Figure 22 - Localization of selected target sequences for TOR1AIP1 gene. The first target sequence includes 
5 nucleotides of the exon 7 (grey) and 14 nucleotides of the exon 8 (green). The second target sequence 
includes 19 nucleotides of the exon 10 (red). Therefore these two oligonucleotides are directed against the 
exon 7/8 and exon 10, respectively. 
13.2. Oligonucleotides design 
For each shRNA selected target sequence, the synthesis of two complementary 
oligonucleotides was required: a top strand (including the target sequence) and a 
complementary bottom strand. For this purpose, the oligonucleotides were properly 
designed (Figure 23) using a bioinformatic tool (Clontech designer). We called 
“oligonucleotide 1” to target sequence directed for exons 7 and 8 of TOR1AIP1. The 
oligonucleotide that includes the target sequence for exon 10 was named “oligonucleotide 
2”. 
 
Figure 23 - Designed oligonucleotides (1 and 2) for TOR1AIP1 gene. Top and bottom strands are 
represented 5’ to 3’. The unique restriction site (Mlu I) allows the confirmation of insertion of the clones 
after ligation (ACGCGT). 5' BamH I and 3' EcoR I overhangs are necessary for further directional cloning into 
the vector. Target sense sequence (orange); TTCAAGAGA (hairpin loop); antisense sequence (blue); 
terminator sequence (underlined); restriction sites (grey). Available on 
http://bioinfo.clontech.com/rnaidesigner/oligoDesigner.do. 
GTGCTAAGCTCAGGATATC
1296 - 1315 bp
GGAAGAGACACTTGGAACA
2009 -2027 bp
1 2 3 4 5 6 7 8 9 10
TOR1AIP1
mRNA
4054 bp
Oligonucleotides 1
Target sequence for exons 7 and 8 of TOR1AIP1
Top Strand: 5' gatcc GTGCTAAGCTCAGGATATC TTCAAGAGA GATATCCTGAGCTTAGCACTTTTTTACGCGT g 3'
Bottom Strand: 5' aattc ACGCGTAAAAAA GTGCTAAGCTCAGGATATC TCTCTTGAA GATATCCTGAGCTTAGCAC g 3'
_____________________________________________________________________________________
Oligonucleotides 2
Target sequence for exon 10 of TOR1AIP1
Top strand: 5' gatcc GGAAGAGACACTTGGAACA TTCAAGAGA TGTTCCAAGTGTCTCTTCCTTTTTTACGCGT g 3'
Bottom strand: 5' aattc ACGCGTAAAAAA GGAAGAGACACTTGGAACA TCTCTTGAA TGTTCCAAGTGTCTCTTCC g 3'
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Once designed and commercial synthesized, the oligonucleotide 1 and oligonucleotide 
2 were annealed and then ligated into the vector pSIREN-retroQ. Next, E. coli XL1-blue was 
transformed with the shRNA constructs for further DNA isolation. Finally, the cloning of 
constructs was confirmed through restriction analysis and sequencing (Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 24 - Schematic illustration of shRNA cloning into the pSIREN-retroQ vector. As an example, this figure 
represents the oligonucleotide 1 that allows the generation of shRNA against exon 7/8 (construct 1). The 
restriction endonucleases BamH I and EcoR I were used to open the vector, while Mlu I and Sal I allowed the 
confirming restriction analysis. 
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Annealed oligonucleotide 2 
BamH I    Target Sense Sequence        Hairpin Loop       Antisense Sequence      Mlu I 
5'  gatcc GGAAGAGACACTTGGAACA   TTCAAGAGA TGTTCCAAGTGTCTCTTCC    TTTTTT    ACGCGT g 3' 
3' g CCTTCTCTGTGAACCTTGT AAGTTCTCT ACAAGGTTCACAGAGAAGG AAAAAA TGCGCA cttaa 5' 
              EcoR I 
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13.2.1. shRNA oligonucleotides annealing 
The top and bottom strands of each oligonucleotide (oligonucleotide 1 and 
oligonucleotide 2) were annealed, as represented in Figure 25. 
 
Figure 25 - Annealed oligonucleotides (1 and 2). Top strand are shown 5’ to 3’ and bottom strand 3’ to 5’. 
Target sense sequence (orange); TTCAAGAGA (hairpin loop); antisense sequence (blue); terminator sequence 
(underlined); restriction sites (grey). 
 
Additionally, the annealing of the negative control (missense oligonucleotide obtained 
commercially) was also performed. The sense sequence of the latter does not align with any 
human transcript (Figure 26). 
 
Figure 26 - Annealed negative control (missense oligonucleotide obtained commercially). The target 
sequence of the negative control does not align with any human transcript. Target sense sequence (orange); 
TTCAAGAGA (hairpin loop); antisense sequence (blue); terminator sequence (underlined); restriction sites 
(grey). 
 
After the annealing step, the oligonucleotides were cloned into the pSIREN-retroQ 
vector and the resulting constructs were further selected and isolated. From now long, we 
Annealed oligonucleotide 1
BamH I  Target Sense Sequence Hairpin Loop Antisense Sequence Mlu I
5' gatcc GTGCTAAGCTCAGGATATC TTCAAGAGA   GATATCCTGAGCTTAGCAC TTTTTT ACGCGTg 3'
3’ g  CACGATTCGAGTCCTATAG AAGTTCTCT   CTATAGGACTCGAATCGTG AAAAAA TGCGCA cttaa 5’
EcoR I
Annealed oligonucleotide 2
BamH I  Target Sense Sequence Hairpin Loop Antisense Sequence Mlu I
5'  gatcc GGAAGAGACACTTGGAACA TTCAAGAGA TGTTCCAAGTGTCTCTTCC TTTTTT ACGCGT g 3'
3‘ g CCTTCTCTGTGAACCTTGT AAGTTCTCT ACAAGGTTCACAGAGAAGG AAAAAA TGCGCA cttaa 5'
EcoR I
BamH I Target Sense Sequence Hairpin Loop Antisense Sequence
5'  gatcc GCTTCATAAGGCGCATAGCTA TTCAAGAGA  TAGCTATGCGCCTTATGAAGC TTTTTT g 3'
3‘ g CGAAGTATTCCGCGTATCGAT AAGTTCTCT ATCGATACGCGGAATACTTCG AAAAAA  cttaa 5'
EcoR I
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will entitle pSIREN-retroQ constructs as huLAP1B construct 1 and huLAP1B construct 2, 
corresponding to the oligonucleotide 1 and oligonucleotide 2, respectively. 
13.2.2. Restriction analysis 
The restriction digestion of the positive clones was performed to confirm the 
presence of positive results that correspond to the correct insertion of both oligonucleotides 
into the pSIREN-retroQ. The results are presented in Figure 27 and revealed the presence of 
two fragments: one of approximately 1440 bp that corresponds to the weight of 
oligonucleotide 1 or 2 (65 bp) plus part of the vector (1375 bp) and a second fragment of 
5070 bp that corresponds to the rest of the vector. Therefore, the presence of both 
oligonucleotides was confirmed since two fragments with the expected size were obtained. 
The two observed fragments (Figure 27A and B) demonstrated that Mlu I enzyme cleaved the 
unique restriction site within each oligonucleotide and Sal I cleaved within the pSIREN-retroQ 
vector, as expected. The positive results with restriction digestion were further confirmed by 
automated DNA sequencing. 
  
Figure 27 - Restriction analysis of both human LAP1B constructs.  A) Lane 1, 1 Kb
+
 DNA ladder (Invitrogen); 
Lane 2, Positive clones (digested pSIREN-retroQ vector; oligonucleotide 1 + part of the vector) digested with 
Mlu I and Sal I restriction endonucleases. B) Lane 1, 1 Kb
+
 DNA ladder; Lane 2, Positive clones (digested 
pSIREN-retroQ vector; oligonucleotide 2 + part of the vector) with Mlu I and Sal I restriction enzymes. 
13.2.3. DNA sequencing 
The confirmation of both constructs was achieved through DNA sequencing, using an 
appropriate primer (see appendix - vector information). Some ambiguities were seen and the 
sequences were further confirmed by visual analysis. The results for both constructs are 
presented in Figure 28A (huLAP1 construct 1) and Figure 28B (huLAP1 construct 2). 
1 2 21
5000 bp
2000 bp
1650 bp
5000 bp
2000 bp
1650 bp
Digested p SIREN 
vector
Oligonucleotide 1 + 
part of the vector
Digested p SIREN 
vector
Oligonucleotide 2 + 
part of the vector
A B
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Figure 28 - Sequencing analysis of the pSIREN-retroQ constructs for human LAP1B. A) Sequencing analysis 
of the pSIREN-retroQ construct 1. B) Sequencing analysis of the pSIREN-retroQ construct 2. The 
oligonucleotide sequence was confirmed (blue) through the FinchTV software (Geospiza, Inc.). 
14. ESTABLISHMENT OF SH-SY5Y CELLS TRANSFECTION CONDITIONS FOR huLAP1 
shRNA CONSTRUCTS 
The human neuroblastoma SH-SY5Y cells were transfected with each human LAP1 
shRNA construct (huLAP1 construct 1 and huLAP1 construct 2) separately and also with both 
constructs, simultaneously (Figure 29). Their effect on huLAP1 knockdown was monitored by 
SDS-PAGE, followed by immunoblotting using a specific antibody against LAP1 as already 
described in Materials and Methods. The effect was evaluated for the well characterized 
huLAP1B isoform and also for the one we believe that is the human LAP1C, which is likely to 
be the most abundant isoform of LAP1 in cultured cells. 
 
Figure 29 - Schematic representation of the procedure used for determination of the efficiency of 
interfering shRNA constructs. The transfection conditions were optimized and SH-SY5Y cells were 
transfected with both huLAP1 shRNA constructs. 
Essentially, we tested two different transfection reagents (Lipofectamine and 
TurboFect), two different DNA concentrations (2 μg and 5 μg) and also two different periods 
GATCC GTGCTAAGCTCAGGATATC TTCAAGAG GATATCCTGAGCTTAGCAC TTTTTT ACGCGT G
GATCC GGAAGAGACACTTGGAACA TTCAAGAGA TGTTCCAAGTGTCTCTTCC TTTTTT ACGCGT G
A
B
Transfection of 
SH-SY5Y with 
shRNA 
constructs 
SDS-PAGE 
Immunoblotting 
→ Anti-LAP1 
Human LAP1B/C 
knockdown 
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of transfection incubation (24 hours and 48 hours). The transfection conditions were 
optimized to establish the best RNA interference efficiency. 
14.1. Optimization of cell transfection conditions 
Two different amounts of each shRNA construct (2 μg and 5 μg) as well as two distinct 
transfection methodologies (using Lipofectamine 2000TM and TurboFectTM) were used. The 
protein levels of the huLAP1 were quantified 24 hours (Figure 30) and 48 hours (Figure 31) 
upon transfection. Concerning to knockdown efficiency, it was evaluated the effect of the 
shRNA constructs on the expression of the two human LAP1 isoforms (huLAP1B and 
huLAP1C). Moreover, expression of LAP1 isoforms was always compared between cells 
transfected with the shRNA control and cells transfected with the LAP1 specific shRNAs. The 
levels of huLAP1B and huLAP1C were quantified by densitometry and plotted upon their 
correction to the loading control (Ponceau S). 
 
14.1.1. 24 hours post-transfection 
Using the Lipofectamine methodology for 24 hours (Figure 30A and C) the knockdown 
results were more evident for huLAP1B than huLAP1C. In overall, for huLAP1C all tested 
conditions produced a quite similar interference percentage around 20-40% (Figure 30C). 
However, for huLAP1B isoform, the knockdown efficiency was higher using 5 μg of each 
tested construct and the achieved interference using the construct 1, construct 2 and both 
together was approximately 40%, 40% and 60%, respectively (Figure 30A). However, when 
the cells were transfected for 24 hours using the TurboFect reagent, with the same amounts 
of each construct, the results were more evident for huLAP1C isoform. We could observe 
interferences around 70%, 60% and 80% (Figure 30D) for 5 μg of Construct 1, Construct 2 and 
Construct 1 and 2, respectively. For human LAP1B isoform, the interferences are quite lower 
and were around 35%, 25% and 50% for each construct (Figure 30B). Upon 24 hours of 
transfection, the maximum knockdown efficiency was observed in TurboFect transfection 
with both construct 1 and 2 together, where was achieved 80% of interference for huLAP1C. 
Indeed, it was also achieved an acceptable knockdown, around 40%, with the Lipofectamine 
reagent with the same time of transfection.  
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14.1.2. 48 hours post-transfection 
Surprisingly, upon 48 hours of transfection the effects of knockdown were not so clear 
than those observed with 24 hours of transfection using the same two methodologies and 
DNA concentrations. The SH-SY5Y cells transfected with Lipofectamine for 48 hours produced 
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Figure 30 - Knockdown levels of human LAP1B/C 24 hours upon shRNA transfection. The transfection with 
Lipofectamine (left column) and TurboFect (right column) was tested using 2 μg and 5 μg of shRNA 
constructs. The knockdown was evaluated for both LAP1 isoforms: huLAP1B (A, B) and huLAP1C (C, D). AU, 
arbitrary units; C1, shRNA construct 1; C2, shRNA construct 2; C1+C2, construct 1 and 2; huLAP1, human 
LAP1. 
A B 
C D 
5 μg2 μg 5 μg 2 μg 2 μg 5 μg 2 μg 5 μg 5 μg2 μg 5 μg 2 μg 2 μg 5 μg 2 μg 5 μg
5 μg2 μg 5 μg 2 μg 2 μg 5 μg 2 μg 5 μg 5 μg2 μg 5 μg 2 μg 2 μg 5 μg 2 μg 5 μg
huLAP1B  
  68 kDa  - 
Control C1 C2 C1+C2 
huLAP1B  
  68 kDa  -   
Control C1 C2 C1+C2 
huLAP1C  
  55 kDa  -  
Control C1 C2 C1+C2 
huLAP1C 
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a knockdown not so significant, even with the two concentrations tested. Therefore, the 
obtained interference for huLAP1B isoform using 5 µg of the construct 1, construct 2 and 
both constructs together were around 40%, 25% and 60%, respectively (Figure 31A). For the 
huLAP1C isoform, the percentages were approximately 40%, 10% and 50% (Figure 31C).  
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Figure 31 - Knockdown levels of human LAP1B/C 48 hours upon shRNA transfection. The transfection 
with Lipofectamine (left column) and TurboFect (right column) was tested, both with 2 μg and 5 μg of 
shRNAs. The knockdown was evaluated for huLAP1B (A, B) and huLAP1C (C, D). AU, arbitrary units; C1, 
shRNA construct 1; C2, shRNA construct 2. 
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Using the TurboFect reagent during same period of time, unexpected results were 
observed, using 5 μg of constructs, since a very low interference was achieved. However, the 
interference for huLAP1B isoform using 2 µg was 40%, 40% and 50% (Figure 31B) for 
construct 1, construct 2 and both constructs together, respectively. For the huLAP1C isoform, 
the observed knockdown was approximately 10%, 5% and 0% (Figure 31D), respectively. 
All together, these results point that the optimized transfection conditions for a 
higher knockdown efficiency are the ones achieved interference using the TurboFectTM 
transfection reagent, whereby 5 μg of shRNA each construct were transfected. The time of 
transfection that proved to be more effective for knocking-down LAP1 was 24 hours. The 
percentages of interference for all tested conditions are visualized in the next Table 6, where 
the best conditions are highlighted in red. 
 
Table 6 - Knockdown efficiency of human LAP1B/C using several transfection conditions. Two different 
transfection reagents were used (Lipofectamine and TurboFect) as well as two different time points post-
transfection (24 hours and 48 hours). Two DNA concentrations were also tested (2 μg and 5 μg) with both 
constructs. C1, construct 1, C2, construct 2; C1+C2, construct 1 + 2. Optimized conditions are seen in red. 
LipofectamineTM TurboFectTM 
24 Hours 
Isoforms μg of DNA 
Knockdown 
efficiency (%) 
(C1; C2; C1+C2) 
Isoforms μg of DNA 
Knockdown 
efficiency (%) 
(C1; C2; C1+C2) 
huLAP1B 
2 μg 40, 40, 60  
huLAP1B 
2 μg 40, 20, 50  
5 μg 40, 40, 60  5 μg 35, 25, 50  
huLAP1C 
2 μg 30, 30, 40  
huLAP1C 
2 μg 60, 40, 60  
5 μg 20, 30, 40  5 μg 70, 60, 80  
LipofectamineTM TurboFectTM 
48 Hours 
Isoforms μg of DNA 
Knockdown 
efficiency (%) 
(C1; C2; C1+C2) 
Isoforms μg of DNA 
Knockdown 
efficiency (%)  
(C1; C2; C1+C2) 
huLAP1B 
2 μg 55, 30, 40 
huLAP1B 
2 μg 40, 40, 50 
5 μg 40, 25, 60 5 μg 15, 25, 10 
huLAP1C 
2 μg 40, 15, 40 
huLAP1C 
2 μg 10, 5, 0 
5 μg 40, 10, 50 5 μg 10, 0, 5 
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15. TO DETERMINE THE EFFECTS OF huLAP1 KNOCKDOWN  USING BIOCHEMICAL 
ASSAYS 
Once determined the best conditions for interfering with LAP1, that correspond to 
transfection with 5 µg of each construct using the TurboFectTM reagent for 24 hours, we 
performed additional experiments, in order to determine the effects of knocking-down LAP1B 
for the cell integrity, particularly NE integrity and microtubules dynamics. For that we have 
chosen to evaluate the intracellular levels of several proteins, including LAP1 (LAP1B and C) to 
confirm the efficiency of knocking-down, laminB1 to confirm NE integrity, α-tubulin 
acetylated to evaluate the microtubule dynamics and also cleaved poly(ADP-ribose) 
polymerase (PARP) for the overall analysis of cellular integrity. Analyzing the intracellular 
levels of both LAP1B and LAP1C revealed that we interfere with both isoforms as we expected 
and for huLAP1B isoform, the interferences were around 30%, 20% and 50% for each 
construct. We observe interferences around 70%, 60% and 80% for 5 μg of the shRNA 
constructs (construct 1, construct 2 and construct 1+2) when huLAP1C was knocked-down 
(Figure 32).  
 
 
 
 
 
 
 
 
 
 
Figure 32 – Intracellular levels of human LAP1B/C after 24 hours of shRNA transfection  with TurboFect
TM
. 
A) Levels of human LAP1B; B) Levels of human LAP1C. AU, arbitrary units; C1, shRNA construct 1; C2, shRNA 
construct 2. 
Once confirmed that knockdown of huLAP1B was achieved, the intracellular levels of 
the other three proteins were evaluated by immunoblotting. The intracellular levels of 
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laminB1, which is a crucial protein of the nuclear lamina was evaluated (Figure 33). A 
decrease of laminB1 intracellular levels was observed, achieving 70% after transfection of 
construct 2. Also with construct 1 and 2 together a significant decrease of laminB1 was 
observed (approximately 60%). 
 
 
Figure 33 - LaminB1 intracellular levels after huLAP1 knockdown in SH-SY5Y cells. Cells were transfected 
with shRNA control, construct 1, 2 or both for 24h using TurboFect. The amount of lamin B1 decreased 
when huLAP1 is knocked-down. LaminB1 is part of the nuclear lamina, interacting with huLAP1. AU, 
arbitrary units; C1, shRNA construct 1; C2, shRNA construct 2; C1+C2, shRNA construct 1 and 2. 
 
In overall a dramatic change in laminB1 expression is observed with all constructs 
being more pronounced with construct 2. In order to evaluate the microtubules dynamics, 
which is an indirect measure of cytoskeleton integrity, the acetylated α-tubulin was 
quantified after huLAP1 knock-down. There is a considerable decrease in acetylated α-tubulin 
reaching 50% when the two constructs, C1 and C2, were transfected together (Figure 34). 
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Figure 34 - Acetylated α-tubulin intracellular levels after huLAP1 knockdown in SH-SY5Y cells.  Cells were 
transfected with shRNA control, construct 1, 2 or both for 24h using TurboFect. The amount of acetylated 
α-tubulin decreased with the knockdown of huLAP1. Acetylated α-tubulin composes the cellular 
cytoskeleton, especially the microtubules of mitotic spindle. AU, arbitrary units; C1, shRNA construct 1; C2, 
shRNA construct 2; C1+C2, shRNA construct 1 and 2. 
 
PARP is a DNA-binding enzyme that is cleaved by caspase-3 and -7 during apoptosis. 
Thus, the cleavage of PARP into two fragments of 85 kDA and 25 kDa has been considered 
indicative of caspase activation and has been used as a marker for apoptosis (72,73). The 
antibody that we used to detect cleaved PARP (Millipore) recognizes the 85 kDa fragment. 
The results of cleaved PARP have shown that there is a slight tendency to have increased 
levels particularly with C2 construct (Figure 35). However, no significant alterations were 
observed so far. 
 
0
20
40
60
80
100
Control C1 C2 C1+C2Le
ve
ls
 o
f 
ac
e
ty
la
te
d
 α
-t
u
b
u
lin
 (
A
U
) 
shRNA construct 
Acetylated 
 α-tubulin 
   50 kDa  - 
Control C1 C2 C1+C
2 
Knocking-down LAP1 using the short hairpin RNA strategy 
79 
 
     
Figure 35 – Cleaved PARP levels after huLAP1 knockdown in SH-SY5Y cells. Cells were transfected with 
shRNA control, construct 1, 2 or both for 24h using TurboFect. Transfection of construct 2 caused a slight 
tendency to have increased levels of cleaved PARP. AU, arbitrary units; C1, shRNA construct 1; C2, shRNA 
construct 2. 
 
Additionally, the resazurin cell viability assay was performed to check the presence of 
metabolically inactive and active cells. No significant results were observed among shRNA 
constructs, with all cells exhibiting metabolic activity. 
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16. TO EVALUATE THE EFFECTS OF huLAP1B/C KNOCKDOWN IN CELLULAR INTEGRITY 
BY MICROSCOPY 
SH-SY5Y cells morphology and cytoskeleton integrity was also evaluated through 
fluorescence and confocal microscopy after huLAP1 knockdown. Thus, 450 cells were counted 
per condition: cells transfected with the shRNA control, construct 1, construct 2 or construct 
1 and 2 together. Specifically, the nuclei and the corresponding nuclear envelopes labeled 
with DAPI and anti-LAP1 antibody, respectively, were counted. Immunodetection  of huLAP1 
in the NE was seen to decrease around 50% using both constructs together, while 
approximately 40% of huLAP1 silencing was seen using construct 1 or construct 2 (Figure 36).  
 
 
Figure 36 - Number of visible nuclear envelopes labeled with LAP1 in SH-SY5Y cells after LAP1 knockdown. 
After the immunochemistry, 450 nuclei were counted through the DAPI staining and then the nuclear 
envelopes labeled with LAP1 were also counted through visual analysis on epifluorescence microscope. AU, 
arbitrary units; C1, shRNA construct 1; C2, shRNA construct 2; C1+C2, shRNA construct 1 and 2; huLAP1, 
human LAP1. 
 
Analyses of the intracellular levels of both LAP1 isoforms in this latter knockdown, 
revealed that huLAP1B expression decreases 0%, 10% and 35% using construct 1, construct 2 
and construct 1+2, respectively. We observed interferences for LAP1C around 38%, 43% and 
39% after transfection of construct 1, construct 2 and construct 1+2, respectively (Figure 37). 
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Then, we analyzed SH-SY5Y cells upon LAP1 knockdown by confocal microscopy.  
Additionally, in these same LAP1 knocked-down cells, the morphology of nuclei was 
also analyzed. We evaluated the amount of acetylated α-tubulin as well as its distribution in 
cells, when LAP1 protein is depleted. 
In control cells (Figure 38A), we have seen that LAP1 is present in the perinuclear 
region, while the morphology of the nucleus and the distribution of acetylated α-tubulin was 
normal. In transfected cells with the shRNA construct 1 (Figure 38B), we have seen that LAP1 
was efficiently knocked-down in approximately 50% of cells where it is just visible a punctated 
pattern in membrane and also within the nucleus. In this case, the nucleus has an abnormal 
reniform morphology with a normal distribution of chromatin. Abnormally, the acetylated α-
tubulin is more concentrated in cell shrinkage sites. Concerning transfected cells with 
construct 2 (Figure 38C), the nuclear morphology observed is normal in some cells while is 
reniform in others (not shown). The abnormal distribution of chromatin is also present here 
while a decrease of acetylated α-tubulin staining is also evident. Finally, in both cell 
transfected constructs (Figure 38D), the nuclear morphology observed is normal in some cells 
while is reniform in others. Once more, we observed an abnormal chromatin distribution 
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Figure 37 - Intracellular levels of human LAP1B/C after knockdown. A) Levels of human LAP1B; B) Levels of 
human LAP1C. AU, arbitrary units; C1, shRNA construct 1; C2, shRNA construct 2. 
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while a more pronounced decrease of acetylated α-tubulin staining compared to cells 
transfected with construct 2.  
 
Figure 38 - Effects of LAP1 knockdown in cellular nuclei and acetylated α-tubulin distribution. LAP1 was 
detected using a rabbit anti-LAP1 conjugated to secondary antibody Alexa Fluor® Goat anti-rabbit 594 IgG 
(red). Acetylated α-tubulin was detected using mouse anti-acetylated α-tubulin conjugated to secondary 
antibody Alexa Fluor® Goat anti-mouse 488 IgG (green). Nucleic acids were stained with DAPI (blue). Co-
localization of LAP1, acetylated α-tubulin and DAPI can be observed in the merge figure. A) Control; B) 
shRNA construct 1; C) shRNA construct 2; D) shRNA construct 1+2. Bar, 10 μm. 
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The RNA interference (RNAi) strategy is a specific and selective methodology, through 
which the expression of a targeted gene is knocked-down to mimic what happens at a cellular 
level, if a specific gene is weakly expressed. Therefore, this technique represents a powerful 
approach for unraveling the putative gene function in mammalian cells (46–48). Among the 
several variants of regulatory RNAs, there are the short hairpin RNAs (shRNAs), which are 
processed through expression of shRNA vectors, for example the pSIREN-retroQ. They 
demonstrated to mediate a long-lasting gene silencing of constructs, only using few copies of 
shRNA, since it can be continuously produced by the host cell (46,58). It is believed that less 
than five copies of shRNA integrated in host genome are enough to achieve an effective gene 
knockdown. Such conclusion is a great advantage because it may result in less off-target 
effects. The less off-target effects can also be explained by the endogenous processing and 
nuclear regulation, after the transcription of DNA oligonucleotides into shRNAs (48,69). The 
ability of this method to reduce the expression of a specific gene allows the understanding of 
its physiological function, generating loss-of-function phenotypes (47,50). 
LAP1 proteins are type two integral membrane proteins of to the inner nuclear 
membrane. Thus, they are potential biochemical markers for INM integrity and are very 
useful models for biogenesis studies of the nuclear membranes (1,6,25). LAP1 function 
remains poorly understood and few information is available. Regarding LAP1 isoforms, there 
is information for Rattus norvergicus where 3 isoforms (LAP1A, B and C) were previously 
identified (5). However, only one human LAP1 isoform (LAP1B) was fully sequenced. Using 
human cell lines, we detect mainly two isoforms: LAP1B and a lower molecular weight 
isoform that we hypothesize to be huLAP1C, as previously mentioned (25). Concerning their 
physiological functions, it has been hypothesized that LAP1 may have a role as lamina 
attachment site and assembly to the inner nuclear membrane (4–6). Additional putative 
functions have been proposed to be related with arrangement and structure of lamin 
filaments and reassembly of the NE at the end of mitosis (7). For this purpose, the previously 
described shRNA methodology was applied to mimic the SH-SY5Y cell behavior when we 
reduced the expression of huLAP1, through an induced knockdown. Therefore, the shRNA 
strategy was quite essential for the analysis of LAP1 role in human neuronal-like cells (2,23).  
In order to establish the best knockdown efficiency, the transfection of shRNA 
constructs was evaluated in several conditions. Essentially, we tested two different 
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transfection reagents (Lipofectamine and TurboFect), two different DNA concentrations (2 μg 
and 5 μg) and also two different post-transfection periods (24 hours and 48 hours). As 
negative control, a missense oligonucleotide was also transfected in the same conditions of 
huLAP1B constructs, for comparison. Using the Lipofectamine methodology for 24 hours, the 
knockdown results were somewhat more pronounced for huLAP1B (maximum of 60% of 
interference) than huLAP1C (maximum of 40% of interference), as we expected since the 
selection of target sequences was made from the huLAP1B transcript, the only sequenced 
human LAP1 isoform. Since we also observe interference of huLAP1C, whose sequence is not 
described, our main hypothesis was that the chosen target sequences for huLAP1B have high 
homology with huLAP1C. However, the knockdown results using TurboFect transfection 
reagent in the same conditions (24 hours upon transfection), were more evident for huLAP1C 
(maximum of 80% of interference) than for huLAP1B (maximum of 50% of interference), 
contrary to our expectations.  So, we can assume that the selected LAP1 target sequences for 
knockdown, in fact, seem to be present in both isoforms. 
From all these experiments, we concluded that the chosen LAP1 targeted sequences, 
in fact, interfere with both huLAP1 isoforms. Additionally, we were able to determine that the 
TurboFect methodology produced the best interference results for both isoforms. In fact, 
using the TurboFect reagent for 24 hours it was achieved the best knocking-efficiency 
(maximum of 80% interference).  Such difference can be explained in part by the mechanism 
of action of the different transfection reagents. In the case of TurboFect, the formed 
TurboFect/DNA complexes protect DNA from degradation and the mechanism of 
translocation to nucleus is established. The nuclear translocation happens after the 
endocytosis of the complexes, whose endosomes are further disrupted due to quick osmotic 
swelling (Invitrogen). On the other hand, the mechanism of  Lipofectamine transfection 
reagent is not so clearly understood, and it is known that some concentrations of 
Lipofectamine can be toxic for DNA, affecting the growth, apoptosis and cell cycle (74). 
Using Lipofectamine or TurboFect for 24 hours, the knockdown efficiency was higher 
with 5 μg of each tested construct, since the higher amount of DNA oligonucleotides results in 
more copies of in vivo transcribed shRNAs. Thus, 5 μg of transfected DNA was optimized to 
achieve the interference using the construct 1, construct 2 and both constructs together 
(40%, 40% and 60%). Both constructs together were always the most efficient to induce a 
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better knockdown, since each of them is loaded into one RISC/Ago2 complex. Therefore, in 
this case, two complexes with the shRNA constructs are directed to the two selected target 
sequences of TOR1AIP1 transcript, producing a more efficient degradation of the sequence, 
as we expected. 
Surprisingly, upon 48 hours of transfection, the effects of knockdown were not so 
clear than those observed with 24 hours of transfection using the same two methodologies.  
Using the TurboFect reagent during 48 hours, unexpected results were observed, since for 
the huLAP1C isoform, no significant knockdown was observed. The latter observation could 
be explained by a possible prejudicial effect of TurboFect, upon 48 hours of transient 
transfection with the shRNA constructs.  
In conclusion, the optimized post-transfection time was 24 hours, with the TurboFect 
transfection reagent. The optimized concentration of DNA was 5 μg and transfection of both 
constructs together had revealed the best knockdown efficiency.  
Once determined the best conditions for human LAP1 knocking-down, we evaluated 
biochemically the intracellular levels of three proteins when huLAP1 is depleted: laminB1, 
which is particularly important for NE integrity;  acetylated α-tubulin, a marker for 
microtubules stability; and cleaved PARP for overall cellular integrity evaluation. For that, we 
evaluate the intracellular levels of cleaved PARP, acetylated α-tubulin and laminB1 using 
specific antibodies against which of the proteins.  
Concerning to laminB1 intracellular levels, a significant decrease was observed, upon 
SH-SY5Y cell transfection with all huLAP1 shRNA constructs. Since a tight association of LAP1 
with chromatin proteins and lamina is described, NE fragmentation may occur simultaneously 
with the disruption of these protein-protein interactions. Thus, it is likely that lack of LAP1 
and subsequent disruption of the binding with chromatin proteins lead to nuclear membrane 
disintegration, followed by entire NE disruption. Therefore, B-type lamins also disassembled, 
since they are suspended in the INM. On the other hand, reduction of intracellular laminB1 
levels may be due to the disassembly of the attachment sites of laminB1 to NE through LAP1. 
Thus, without LAP1 protein, the laminB1 may disconnect of the INM, leading to an abnormal 
morphology and instability of the NE. In conclusion, since LAP1 is depleted, we can assume 
that the laminB1 decrease may be explained by the disruption of laminB1 attachment sites to 
NE or, otherwise, by a resulting disintegration of the NE upon LAP1 absence (75). Additionally, 
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it was already observed that laminB-deficient cells undergo apoptosis, regardless of nuclear 
assembly of lamins A/C, suggesting NE targeting of B-lamins is essential for cell survival (76). 
Acetylation of α-tubulin plays is important for stabilizing microtubules structures, 
which are responsive for movement of chromosomes during mitosis and for maintenance of 
cellular morphology. Thus, it allows an indirect measure of cytoskeleton integrity. In order to 
evaluate the microtubules dynamics, the acetylated α-tubulin was quantified upon huLAP1 
knockdown. There is a considerable decrease in acetylated α-tubulin levels after LAP1 
knockdown. Such decreasing may be explained by a possible disruption of the linker of 
nucleoskeleton and cytoskeleton (LINC) complexes. As previously described, LINC complex is 
composed of SUN proteins which are associated with nuclear lamina and nesprins (from 
ONM). Once reduced the intracellular lamina levels and assuming the disintegration of 
lamins, the lamina-associated SUN proteins may disintegrate from LINC complex. Therefore, 
the connection between nucleoskeleton and cytoskeleton may be disrupted, which can 
explain the decreased levels of acetylated α-tubulin. Another possible explanation for 
reduced levels of acetylated α-tubulin, is the impairment of spindle microtubule formation 
during mitosis. Thus, it may result in weak mitotic asters, which may fail to align 
chromosomes. Such assumption may culminate in cell death because mitosis can not 
progress. This hypothesis is also supported by a recent report which suggests that LAP1 is 
associated with microtubule spindle assembly (29,34). In conclusion, the microtubule 
dynamics is impaired and, subsequently, the cytoskeleton integrity becomes compromised 
with decreased levels of LAP1. 
For an overall analysis of cellular integrity we evaluated the levels of a cleaved 
fragment of PARP (85 kDa), which may be considered a marker for apoptosis (72,73). We 
decided to evaluate the apoptosis because the characteristic chromatin condensation is 
secondary to a series of nuclear events, such as proteolytic degradation of specific nuclear 
proteins that include lamins (76). The results of cleaved PARP have shown that there is a 
slight tendency to have increased levels of this protein. However, the ratio with total PARP 
protein should have been evaluated for a more accurate result. 
SH-SY5Y cells morphology and cytoskeleton integrity were also evaluated through 
fluorescence and confocal microscopy, upon huLAP1 knockdown. Through immunoblotting, 
we have seen that intracellular levels of both huLAP1B and huLAP1C isoforms were knocked-
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down. For huLAP1B, we observed interferences around 0%, 10% and 35% (construct 1, 
construct 2 and construct 1+2, respectively) and, for huLAP1C, we observed interferences 
around 38%, 43% and 39% (construct 1, construct 2 and construct 1+2, respectively). These 
interference percentages are coincident with the cellular nuclear envelope counts, through 
fluorescence microscopy. 
Then, we analyzed the same knocked-down cells by confocal microscopy. In control 
cells, we have seen that LAP1 is present in the perinuclear region, while the nuclear 
morphology and the distribution of acetylated α-tubulin were normal. In transfected cells 
with construct 1, the nucleus presents an abnormal morphology and a distinct concentration 
of acetylated α-tubulin around the nucleus, which may be a sign of cell shrinkage or even by 
compensatory stabilization of NE architecture. In this case, huLAP1B was not efficiently 
knocked-down, so these alterations should arise from huLAP1C deficiency. In transfected cells 
with construct 2, there is also evidence of reniform nuclei and abnormal distribution of 
chromatin within the nucleus. We may hypothesize that huLAP1B seems to be partially 
involved with chromatin distribution, since in this condition an additional interference with 
huLAP1B was obtained (10%), compared to the last case for construct 1. This chromatin 
condensation can be explained as a consequence of laminB1 disintegration, which may result 
in the beginning of the apoptotic process. 
Subsequently, decreased levels of acetylated α-tubulin were observed. In transfected 
cells with both constructs, this condition seems to represent an intermediary phenotype, 
since the nuclei are reniform and chromatin is also abnormally distributed. It can be explained 
by the similar percentage of interference of both isoforms (39% for LAP1C and 35% for 
LAP1B). The acetylated α-tubulin levels are reduced probably because of lack of NE integrity. 
The abnormal distribution of chromatin within the nucleus is also observed and probably 
happens because of the LAP1 disrupted interaction with laminB1. 
LAP1 associates with mitotic chromosomes (4) and, therefore, with decreased levels 
of LAP1, it may lead to an abnormal distribution within nuclei (construct 2 and construct 1+2). 
In conclusion, huLAP1B seems to play a role in chromatin organization. On the other hand, 
decreased levels of acetylated α-tubulin which indicate microtubule instability, may lead to 
fail in chromosome alignment and, subsequently, lead to cell death. Additionally, huLAP1B 
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isoform seems to be involved in decreased levels of tubulin, which may be the result of an 
initial apoptotic process.  
However, more work will be needed to fully evaluate the role of LAP1 on these 
processes. The shRNA strategy would be an important tool to accomplish these objectives.  
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The conclusions of this work are the following: 
 
• The human LAP1 was efficiently knocked-down using TurboFect, 5 μg of DNA and 24h 
post-transfection; 
•  Both constructs together produced the best knockdown efficiency. 
 
•  When LAP1 is knocked-down: 
-   NE integrity is affected (levels of laminB1 decrease); 
-   Microtubule stability is compromised (acetylated α-tubulin  decrease);  
-   Cellular integrity might be affected (slight increase of cleaved PARP). 
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The future perspectives of this work are the following: 
 
 Evaluate apoptosis in knocked-down huLAP1 cells by other approaches 
 Analyze the integrity of the NE through immunofluorescence with laminB1 
antibody in knocked-down huLAP1 cells 
 
 Understand the role of LAP1 in mitosis: 
o Find out novel LAP1 binding partners in mitotic structures  
o Formation and/or stability of the mitotic spindle  
o Reassembly of the nuclear envelope 
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30% ACRYLAMIDE/0,8% BISACRYLAMIDE 
- Weigh 29,2 g of acrylamide 
- Weigh 0,8 g of bisacrylamide 
Dissolve the solutes in distilled water. Make up the volume to 100 mL of deionised 
water and then filter through a 0,2 µm filter and store at 4ºC. 
ALKALINE LYSIS SOLUTIONS 
a) Solution I 
- 50 mM glucose  
- 25 mM Tris-HCl; pH 8.0  
- 10 mM EDTA  
b) Solution II 
- 0,2 N NaOH  
- 1% SDS   
c) Solution III 
- 3 M potassium acetate  
- 2 M glacial acetic acid 
AMPICILIN 
- Weigh 2,5 g of ampicilin sodium salt (50 μg/µL) 
Dissolve the ampicilin in 50 mL of sterile water and filter it through a syringe.  Aliquot 
into sterile microtubes. 
10% APS 
- Weigh 1 g of ammonium persulfate 
Dissolve the solute in 10 mL of deionised water. 
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LURIA-BERTANI MEDIUM (LB MEDIUM) 
- Weigh 25 g of LB 
Dissolve the LB in distilled water and autoclave it for 25 minutes. Next, make up the 
volume of 1 L with distilled water.  
LOADING GEL BUFFER (4X) 
- Add 2,5 mL of 1M Tris solution (pH 6.8) (250 mM) 
- Weigh 0,8 g of SDS (8%) 
- Add 4 mL of glycerol (40%) 
- Add 2 mL of β-Mercaptoethanol (2%) 
- Weigh 1 mg of bromophenol blue (0,01%) 
Adjust the volume to 10 mL of deionised water. Store at room temperature in 
darkness. 
LGB (LOWER GEL BUFFER) 
- Weigh 181,65 g of Tris 
- Weigh 4 g of SDS 
Dissolve the solutes in distilled water. Adjust the pH to 8.9 and make up the volume to 
1L of deionised water. 
MAXIPREP SOLUTIONS 
d) Cell Ressuspension Solution 
- Add 30 mL of Tris-HCl (1M) (Cf = 50mM) 
- Add 6 mL of EDTA (0,5M) (Cf = 10mM) 
- Add 3 mL of RNAse A (10 mg/mL) (Cf = 100 µg/mL) 
Dissolve it and adjust the volume with 264 mL of deionised water. 
e) Cell Lysis Solution 
- Weigh 2,4 g of NaOH (0,2M) 
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- Weigh 3 g of SDS (1%) 
Dissolve the solutes in distilled water. Adjust the volume to 300 mL of distilled water. 
f) Neutralization Solution 
- Weigh 77,73 g of potassium acetate, pH = 4.8 (1,32M) 
Dissolve it in distilled water and adjust the volume to 600 mL with deionised water. 
g) Column Wash Solution 
- Weigh 4,633 g of potassium acetate (0,2M) 
- Add 4,9 mL of Tris-HCl (1M) (Cf = 80 mM) 
- Add 47,2 µL of EDTA (0,5M), (Cf = 40 µM) 
Dissolve the solutes and adjust the volume with 340 mL of distilled water. 
4% PARAFORMALDEHYDE 
- Weigh 4 g of paraformaldehyde 
Dissolve the paraformaldehyde in 25 mL of distilled water by heating at 58ºC. Add 1-2 
drops of 1M NaOH to clarify the solution. Filter the solution (0,2 µm filter) and then add 50 
mL of 2X PBS. Adjust the volume to 100 mL with deionised water. 
1X PBS 
Dissolve one pack of BupH Modified Dulbecco’s Phosphate Buffered Saline Pack 
(Pierce) in 500 mL of deionised water. Final composition: 
- 8 mM of sodium phosphate 
- 2 mM of potassium phosphate 
- 40 mM of NaCl 
- 10 mM of KCl 
Sterilize by filtering through a 0,2 µm filter and store at 4ºC. 
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PLATES OF LB MEDIUM/AMPICILIN 
Plates of LB medium containing ampicilin antibiotic (50 μg/µL) were made. The LB 
medium and agar were weighed and mixed with distilled water. Then, it was autoclaved 
during 20 minutes and, after the cooling to 55°C, the ampicilin was added. The LB/agar 
containing the antibiotic was poured into plates (approximately 20 mL for each). The plates 
have cooled until solidified. 
 
10X RUNNING BUFFER 
- Weigh 30,3 g of Tris (250 mM) 
- Weigh 144,2 g of glycine (2.5 M) 
- Weigh 10 g of SDS (1%) 
Dissolve the solutes in distilled water. Adjust the pH to 8.3 and the volume to 1L. 
RESOLVING GEL SOLUTION (10%) 
- Add 12,35 mL of H2O 
- Add 5 mL of 30% Acryl/0,8% Bisacyl solution 
- Add 7,5 mL of LGB (4X) 
- Add 150 μL of 10% APS 
- Add 15 μL of TEMED 
STACKING (UPPER) GEL SOLUTION (3,5%) 
- Add 6,60 mL of H2O 
- Add 1,2 mL of 30% Acryl/0,8% Bisacyl solution 
- Add 2,0 mL of LGB (4X) 
- Add 200 μL of 10% APS 
- Add 100 μL of 10% SDS 
-  Add 10 μL of TEMED 
10% SDS 
- Weigh 1 g of SDS 
Dissolve the solute in 10 mL of deionised water. 
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SH-SY5Y COMPLETE MEDIUM 
- Weigh 4,805 g of MEM 
- Weigh 5,315 g of F12 
- Weigh 0,055 g of sodium piruvate 
- Weigh 1,5 g of sodium bicarbonate 
- Add 10 mL of Antimycotic antibiotic 
Dissolve the solute in distilled water and adjust pH to 7.2 - 7.4. Add 100 mL of FBS and 
2,5 mL of L-glutamine. Make up the volume to 1L with deionised water and filter (0,2 µm) 
STRIPPING SOLUTION 
- Weigh 3,76 g of Tris-HCl (pH 6.7) (62.5 mM) 
- Weigh 10 g of SDS (2%) 
- Add 3,5 mL of beta-mercaptoetanol (100 mM) 
Dissolve the solutes in deionised water and adjust to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 mL. 
SOB MEDIUM 
- Weigh 25,5 g of SOB Broth 
Dissolve the SOB Broth in distilled water. Add 10 mL of 250 mM KCl (1,86 g of KCl in 
100 mL of deionised water) and then adjust the pH to 7.0 with 5N NaOH. Add 5 mL of a sterile 
solution of 2M MgCl2 (19 g of MgCl2 in 90 mL of distilled water). Complete the volume to 1 L 
with deionised water and autoclave the solution. 
SOC MEDIUM 
SOC medium is similar to SOB medium, except for the presence of 20 mM glucose. 
After the sterilization of SOB medium by autoclaving, it should cool to 60ºC and add 20 mL of 
1M glucose.  
The 1M glucose solution is prepared by weighing 18 g of glucose in 90 mL of distilled 
water. Then, it is dissolved and the volume is adjusted to 1L with deionised water. The 1M 
glucose solution is sterilized by filtration. 
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50X TAE BUFFER 
- Weigh 242 g of Tris base 
- Add 57,1 mL of glacial acetic acid 
- Add 100 mL of 0,5M EDTA (pH 8.0) 
10X TBS 
- Weigh 12,11 g of Tris (10 mM) 
- Weigh 87,66 g of NaCl (150 mM) 
Dissolve the solutes in distilled water. Adjust the pH to 8.0 with HCl and make up the 
volume to 1L of deionised water. 
10X TBST 
- Weigh 12,11 g of Tris (10mM) 
- Weigh 87,66 g of NaCl (150 mM) 
Dissolve the solutes in distilled water. Adjust the pH to 8.0 with HCl and make up the 
volume to 995 mL of deionised water. Add 5 mL of Tween 20 (0,05%). 
1X TRANSFER BUFFER 
- Weigh 3,03 g of Tris 
- Weigh 14,41 mL of glycine 
Dissolve the solutes in distilled water. Adjust the pH to 8.3 with HCl and make up the 
volume to 800 mL with distilled water. Add 200 mL of methanol (20%). 
UGB (UPPER GEL BUFFER) 
- Weigh 75,69 g of Tris 
Dissolve the solutes in distilled water. Adjust the pH to 6.8 and make up the volume to 
1L of deionised water. 
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VECTOR INFORMATION 
 
 
 
 
 
 
 
 
Restriction Map and Cloning Site of the RNAi-Ready pSIREN-RetroQ Retroviral Vector (Clontech). Unique 
restriction sites are in bold. RNAi-Ready pSIREN-RetroQ is a self-inactivating retroviral expression vector 
designed to express a short hairpin RNA (shRNA) using the human U6 promoter (RNA Polymerase III-
dependent). This vector is used for targeted gene silencing when a dsDNA oligonucleotide encoding an 
appropriate shRNA is ligated into the vector. The vector contains a puromycin resistance gene for the 
selection of stable transfectants. This retroviral vector is optimized to eliminate promoter interference 
through self-inactivation, which is provided by a deletion in the 3' LTR enhancer region. The hybrid 5' LTR 
consists of the cytomegalovirus (CMV) type I enhancer and the mouse sarcoma virus (MSV) promoter. 
pSIREN-RetroQ also contains a bacterial origin of replication and E. coli Ampicilin
 
resistance gene for 
propagation and selection in bacteria. U6 Forward Sequencing Primer: 6188-6206 (5’- 
GGGCAGGAAGAGGGCCTAT - 3’). 
